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 Chikungunya fever is caused by Chikungunya virus (CHIKV), an infectious disease that 
is characterized by severe joint and muscle pain in humans. The latest outbreak of CHIKV, 
which began in 2005, has affected millions of people across India, Singapore, and the Indian 
Ocean Island region. Type I interferon (IFN), which mediates protection against many different 
viruses through the upregulation of interferon stimulated genes (ISGs), has been shown to be 
essential for the control of CHIKV infection. As the role of ISGs during CHIKV infection is 
largely unknown, we investigated the activity of the interferon stimulated gene ISG15.  
 ISG15 is a ubiquitin like molecule that has the ability to conjugate to intracellular 
proteins and can also be found as a free form both intra- and extracellularly. ISG15 conjugation 
has previously been shown to be essential for protection against influenza B and Sindbis virus 
infections. We demonstrate that neonatal ISG15
-/-
 mice are profoundly more susceptible to 
CHIKV infection compared to WT mice. Unlike other viral models, mice lacking the ability to 
form ISG15 conjugates through the deletion of the E1 enzyme UbE1L, do not display an increase 
in CHIKV induced lethality.   In addition, we observed no differences in viral loads between 
wild type and ISG15
-/- 
mice during the course of the infection.  Instead, ISG15
-/-
 mice displayed a 
xii 
 
dramatic increase in proinflammatory cytokines and chemokines. Our data suggests that the role 
of ISG15 during CHIKV infection is conjugation independent and that ISG15 protection is 
mediated not through its action as an antiviral molecule, but through regulation of the immune 
response.  
To identify potential mechanisms of action for unconjugated free ISG15, we 
characterized both intra- and extracellular forms of ISG15 using mass spectrometry. We identify 
phosphorylation as a potential post-translational modification for extracellular ISG15 and 
identify the secreted 30kDa ISG15 conjugate as ISG15 bound to hemoglobin subunit beta-1. We 
also identify over 140 potential non-covalent binding partners for intracellular ISG15 that are 
involved in many different cellular pathways, including innate immunity, vesicular sorting, and 
cell signaling. Based on our findings, we have generated preliminary data examining a role for 
ISG15 in autophagy as well as a role for ISG15 in the regulation of cytokine production. Our 
characterization of both intra- and extracellular ISG15 will hopefully guide future experiments 
needed to determine the mechanism by which ISG15 regulates the host response to viral 
infection.      
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Introduction 
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Overview 
 
 In 2005, a large scale outbreak of Chikungunya Virus (CHIKV) was reported on the 
Indian Ocean Island of La Reunion, where approximately 1/3 of the 770,000 inhabitants became 
infected (1, 2). The scale and severity of this outbreak in combination with additional concurrent 
outbreaks in India and Southeast Asia has brought this virus to the forefront of infectious disease 
studies. Research on CHIKV has greatly expanded in an attempt to understand both the viral life 
cycle as well as the host response to infection. Critical to the control of CHIKV infection is the 
induction of type I interferons (IFN) (3-5). Interferons, named for their ability to “interfere” with 
viral replication, act by generating an antiviral state within host cells (6-8). Type I IFN mediates 
protection through the upregulation of hundreds of interferon stimulated genes (ISGs), although 
how ISGs provide protection is not well understood. In our introduction, we give an overview of 
our current knowledge of CHIKV, the type I IFN response, as well as the interferon stimulated 
gene ISG15. 
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Chikungunya Virus 
History of CHIKV outbreaks (Epidemiology) 
Chikungunya virus (CHIKV) was originally isolated in Tanzania in 1952 (9). Since then, 
CHIKV has been documented to be responsible for numerous outbreaks across Africa and 
Southeast Asia. Repeated isolated outbreaks of CHIKV have been reported in southern, eastern, 
and western Africa between the 1960s-1990. In the 1960s, CHIKV was reported in Asia, causing 
major outbreaks in Myanmar, Thailand, Sri Lanka and India (10). Sporadic outbreaks were also 
reported in Thailand, Indonesia and the Philippines in the 1980s and Malaysia in the 1990s (11). 
Phylogenic analysis suggests that CHIKV originated in Africa and subsequently spread to Asia. 
Currently there are three evolutionary clades of CHIKV, including West African strains, Eastern, 
Central and Southern African strains (ECSA) and a third clade from Asia (12).    
The most recent large scale outbreak of CHIKV began in Kenya in 2004, spreading to the 
Comoros and eventually appearing on La Reunion Island in March of 2005 (13, 14). The peak of 
the La Reunion outbreak occurred in December 2005-April 2006, where 38% of the population 
became infected and 237 deaths were attributed to CHIKV infection (15). The epidemic soon 
spread to surrounding islands, including Comoros, Mayotte, Mauritius and Madagascar. An 
estimated 1.6 - 6 million cases were reported in India from 2006-2007 (16-18). The epidemic 
also affected areas of Southeast Asia, with outbreaks in Thailand, Singapore and Indonesia. 
Phylogenic studies have confirmed that the ECSA clade was responsible for the 2005-2009 
epidemic (1, 2).            
Imported cases of CHIKV from travelers returning from these areas to the U.S., Europe, 
and other countries fueled fears of large outbreaks in previously unexposed urban populations. 
Increased global communication and travel may make it possible for easier spread of the virus, 
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which was exemplified by a small outbreak (250 cases) in Italy in 2007 and in Southern France 
in 2010 (19-21). As a result, research on CHIKV has greatly increased over the last ten years in 
an attempt to gain a better understanding of CHIKV pathogenesis (11). 
 
Transmission and Viral Vectors 
 CHIKV is an arbovirus, a virus that is transmitted by arthropod vectors. CHIKV is 
transmitted to humans primarily by mosquitoes. There are two distinct transmission cycles for 
CHIKV: (1) sylvatic and (2) human-mosquito-human. Sylvatic transmission is confined to 
Africa, where outbreaks normally affect smaller populations and are dependent on forest-
dwelling Aedes mosquito species, including Aedes furcifer, Aedes taylori, Aedes luteocephalus, 
Aedes africanus, and Aedes neoafricanus. Monkeys, birds, rodents and other vertebrate species 
serve as reservoirs for CHIKV outside of epidemic periods (11). The absence of sylvatic 
transmission in Asia provides additional evidence that CHIKV originated in Africa before being 
introduced in Asia.  
 Non-sylvatic transmission, human-mosquito-human transmission, is dependent on 
mosquitoes that live in urban areas with a close association with humans. In Asia, Aedes Aegypti 
has been described as a predominant vector for CHIKV. However, a new mosquito vector has 
been described following the La Reunion outbreak: Aedes Albopictus. CHIKV La-Reunion 
shows only 1-2% amino acid changes when compared to the Tanzania CHIKV reference strain 
(3). The impact of these mutations on the pathogenicity of the La-Reunion CHIKV strain is not 
well understood, however research has shown that a mutation in the E1 protein of CHIKV is in 
part responsible for the use of Aedes Albopictus as a new viral vector (22). It is postulated that 
the alanine to valine amino acid change at position 226 in the E1 CHIK protein allows for 
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decreased dependency on cholesterol for CHIKV growth, allowing for adaptation in Aedes 
Albopictus. Additional mutations found in the E2 La Reunion envelope protein, E2- G60D and 
E2- I211T, are thought to maximize the effectiveness of the E1 A226V mutation for Ae 
Albopictus infectivity (23).  
 Aedes Albopictus as a new mosquito vector adds to concerns of increased global 
outbreaks for CHIKV due to wide distribution of this vector in urban and Western populations. 
Aedes Albopictus is found in temperate regions where Aedes Aegypti is scarce, including parts of 
the U.S., Europe, China and Japan (11). Ae. Albopictus has the ability to colonize various 
ecosystems and may be a difficult vector to control.    
 
Symptoms (Acute and Long Term) 
Chikungunya in Makonde language translates to “that which bends up,” which refers to 
stooped posture developed during infection resulting from severe muscle and joint pain (11). 
More than 95% of CHIKV infected adults are symptomatic (24). Patients that are infected with 
CHIKV suffer from polyarthralgia, myalgia, asthenia, fever, headache, and rash. Symptoms may 
also include acute tenosynovitis and gastrointestinal complaints (1, 11). Acute symptoms usually 
persist for 1-10 days. During the outbreak on La-Reunion, novel disease symptoms were also 
described that had previously not been reported for CHIKV, including respiratory or kidney 
failure, lymphopenia, lethal hepatitis and encephalopathy (25). In addition, although CHIKV can 
normally be resolved by healthy individuals, La-Reunion reported approximately 250 deaths, 
seen in infants and elderly (26). Several animal models have been developed that mimic the 
symptoms observed during CHIKV infection in humans (27-30).   
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Chronic arthralgia can persist weeks, months, or even years after initial infection. 
Symptoms usually include fluctuating joint pain that does not change in anatomical location. 
Virus is usually not detected in circulation after 2 weeks by RT-PCR, although IgM specific 
responses can persist years after infection. Chronic symptoms normally correlate with age, viral 
load and CRP (C-reactive protein) levels observed during acute infection (31). It remains unclear 
whether chronic symptoms result from poor regeneration of joint tissue following damage during 
acute infection, autoimmune disease induced during infection, or whether the virus is able to 
persist at low levels in select tissues (30).  
 
CHIKV classification 
 Chikungunya virus belongs to the Alphavirus genus and is a member of the Togaviridae 
family. The alphavirus genus can be further subdivided in to 7 antigenic complexes based on 
serological cross reactivity: Barmah Forest (BF), Eastern equine encephalitis (EEE), Middelburg 
(MID), Ndumu (NDU), Semliki Forest (SF), Venezuelan equine encephalitis (VEE), and 
Western equine encephalitis (WEE) (32).  CHIKV belongs to the Semliki Forest Complex. 
Alphaviruses were also once classified by their geographic prevalence in to Old World and New 
World Viruses. Old world alphaviruses are mostly arthrogenic and include Chikungunya virus, 
O’Nyong Nyong Virus (ONNV), Semliki Forest (SFV), Sindbis virus (SIN) and Ross River 
(RRV). In contrast, new world alphaviruses cause encephalitis and include Venezuelan, Eastern 
and Western Equine Encephalitis viruses (33).  
 
CHIKV genome and replication 
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 Chikungunya, like all alphaviruses, is an enveloped positive sense, single stranded RNA 
virus. Electron microscopy indicates that CHIKV is about 70nm in diameter (34). General steps 
regarding the replication cycle for CHIKV is largely deduced from data obtained from other 
Alphaviruses and is supported by the sequence similarities that are conserved in CHIKV (32).  
The genome is enclosed by capsid proteins (C) that form a nucleocapsid, which is 
enveloped in a host-derived lipid bilayer that contains two viral envelope glycoproteins E1 and 
E2. These envelope proteins are necessary for receptor binding (E2) and membrane fusion (E1) 
of host cells. The receptor for CHIKV is unknown, and is likely responsible for restricting the 
tropism of CHIKV. The primary targets of CHIKV infection are thought to be fibroblasts, found 
in the muscle and connective tissue (4). Epithelial (HeLa, 293T, Vero) and endothelial 
(TrHBMEC) cell lines also support CHIKV growth (3). Unlike RRV or VEEV, most 
hematopoietic cells do not support CHIKV growth, although replication can be seen in primary 
monocytes and macrophages (3, 30, 35). After receptor binding, virions are endocytosed and the 
nucleocapsid is released into the cytosol following pH mediated conformational changes in the 
E1-E2 dimer that allows for fusion (36-38).  
 Once the nucleocapsid has disassembled, translation of the viral genome and replication 
occurs. The CHIKV genome is approximately 11.8-kb long and is organized as follows: 5’ cap-
nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6k-E1-poly(A)-3’ (32). The four non-structural 
proteins (nsP1-4) are translated directly from the viral genome to form polyprotein P1234 and 
P123 precursors. These polyproteins are processed by an internal viral protease, located within 
nonstructural protein nsP2. The nonstructural proteins are responsible for generation of a 
complementary minus strand RNA, plus strand RNA and subgenomic RNA. The subgenomic 
RNA is derived from the minus strand RNA and is used to generate the structural proteins E1, 
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pE2, Capsid and 6k (a small peptide that may act as a signal sequence for the translocation of 
E1). pE2 is eventually cleaved to generate E2, which forms a heterodimer with E1, and E3, 
which is not incorporated into the virion. The function of E3 is unknown, although may share 
similarities with SINV E3, which is thought to be involved in proper folding of viral envelope 
glycoprotein spike formation (32).      
 Following genome replication and viral protein production, virion assembly occurs via 
nucleocapsid formation in the cytoplasm. Alphavirus capsid proteins contain RNA binding 
domains that allow for incorporation of the genome into the nucleocapsid. The capsid proteins 
oligomerize to form an icosahedral shell which then diffuses freely through the cytoplasm to 
reach the plasma membrane. At the cell membrane, the nucleocapsid obtains a lipid bilayer 
composed of mature envelope glycoprotein spikes that are composed of trimers of E1-E2 
heterodimers. The E2 protein is necessary for interaction with the capsid proteins, leading to 
maturation of the nucleocapsid which then allows for budding (32). 
 
Pathogen recognition and interferon production 
In humans, viremia for CHIKV infection peaks by day 2 p.i., sharply declines during 
days 3 and 4 p.i. and is undetectable by day 5 (39). This quick decline of viremia suggests that 
the innate immune response is critical for the early response to CHIKV infection. As a result, 
current research on CHIKV has focused on understanding the type I interferon response to 
infection. Here, we review the type I interferon signaling pathway and its importance in 
controlling CHIKV infection. 
 
Pattern Recognition Receptors and RNA Virus Detection  
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 Production of type I IFN is dependent on the ability to detect invading pathogens through 
the use of pattern recognition receptors (PRRs). PRR recognize conserved pathogen structures 
known as pathogen-associated molecular patterns (PAMPs). Toll-like Receptors (TLRs), NOD 
like receptors (NLRs), and RIG-I-like receptors (RLRs) are well described PRRs that play a role 
in pathogen detection. Although the signaling components for each PRR can vary, each pathway 
ultimately leads to the activation of NF-κB and/or IRF3, which are necessary for IFN 
transcription (40). 
TLRs contain a luecine-rich repeat (LRR) for detection of PAMPs, a transmembrane 
domain and an intracellular Toll/IL-1 receptor (TIR) domain that mediates downstream 
signaling. TLRs are localized to either the plasma membrane or endosomal compartment and 
respond to bacterial and/or viral components. The primary TLRs responsible for RNA virus 
detection are TLR3 (dsRNA) and TLR7/8 (ssRNA rich in G/U residues) and are localized to the 
endosome. Phagocytosis of nucleic acids from apoptotic or necrotic cells triggers TLR signaling, 
which leads to macrophage or dendritic cell activation. Downstream signaling of TLR3 and 
TLR7/8 is mediated by TRIF and MyD88, respectively, which leads to the production of IFN 
and other pro-inflammatory cytokines (40, 41). 
 The two best described RLRs, RIG-I (retinoic acid-inducible gene I) and MDA5 
(melanoma differentiation-associated gene 5), are both cytosolic RNA sensors that are 
responsible for detecting intracellular RNA viruses. RIG-I and MDA5 contain a C-terminal 
DExD/H box RNA helicase domain for viral RNA recognition and N-terminal caspase-
recruitment and activation domain (CARDs) which mediate downstream signaling (42). RIG-I 
recognizes dsRNA with 5’ triphosphate and MDA5 recognizes long dsRNA. Engagement of 
RIG-I or MDA5 allows for the association with Cardif /IPS-1/MAVS/VISA, which leads to the 
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activation of NF-B (nuclear factor κB), AP-1 (a heterodimer of activating transcription factor 2 
(ATF2) with c-Jun), IRF7 and IRF3 (7, 42). 
NLRs are cytosolic sensors that detect a wide array of PAMPs and other physiological 
stressors and are primarily characterized by their ability to activate the inflammasome. The role 
for NLRs in RNA virus detection is less defined, although recent literature suggests that the NLR 
NOD2 plays a role in the detection of Respiratory Syncytial, Influenza A and Parainfluenza 
viruses (43). NLRX1 has also been shown to regulate IFN production (44). Both NOD2 and 
NLRX1 interact with Cardif, resulting in a similar downstream signaling cascade as RLRs. 
Translocation of NF-B, AP-1 and IRF3/7 to the nucleus allows for type I IFN production (40, 
42).  
 
Interferons  
 There are three classes of IFN: type I, II and III. Type II IFN consists of a single member, 
IFNγ which signals through the IFNγ receptor complex (IFNGR) and mediates broad immune 
responses to pathogens. Type III IFNs consist of IFNlambda1-3 and signal through a receptor 
complex composed of IFNLR1 (IL-28α) and IL-10R2 (IL-10Rβ). The activity of type III IFNs is 
less well known, however it has been proposed that type III IFNs behave similar to type I IFNs. 
Type I IFNs are well characterized and are the focus of this section. (45, 46).  
 Type I IFNs are made up of seven classes: IFN, IFN, IFN, IFN, IFN, IFN, and 
IFN, with IFN and IFN being the focus of antiviral studies. Although there is only one 
subtype for IFN, there are several subtypes of IFN (13 in humans, at least 10 in mice). Type I 
IFNs are regulated at the transcriptional level, following PRR activation. The promoter regions 
of IFNβ and IFNα contain regulatory cis elements called positive regulatory domains (PRDs). 
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The IFNβ promoter contains 4 PRD domains I-IV, whereas IFNα contains PRDI and PRDIII-like 
elements (PRD-LE). PRDI and III are the binding sites for the IRF family members, whereas 
PRDII and PRDIV bind to NF-κB and AP-1, respectively. Binding of transcription factors to the 
promoter region forms an “enhanceosome,” which allows for nucleosome displacement and 
recruitment of the transcription complex TFIID for gene expression. (42)  
After virus has been detected by an infected cell, type I IFN is released, acting in an 
autocrine and paracrine fashion on both infected and uninfected cells. All type I IFNs mediate 
there antiviral activity by binding to a common IFN/ receptor (IFNAR), a complex between 
IFNAR1 and IFNAR2. IFNAR1 and IFNAR2 associate with intracellular Janus activated kinases 
(JAKs) tyrosine kinase 2 (Tyk2) and JAK1 respectively. Tyk2 and JAK1 are trans-
phosphorylated following IFNAR oligomerization. Activation of Tyk2 and JAK1 allows for 
phosphorylation of STAT1 and STAT2 (signal transducer and activator of transcription). 
Phosphorylation of STAT1 and STAT2 allows for dimerization followed by association with 
IRF9. This complex is known as interferon-stimulated response factor 3 (ISGF3). ISGF3 
translocates to the nucleus and activates the transcription of interferon stimulated genes (ISGs) 
by binding to interferon stimulated response elements (ISRE). Hundreds of ISGs are transcribed 
in response to type I interferon signaling although the antiviral function for many of these genes 
remains unknown. (46) 
 
A role for type I IFN during CHIKV infection 
Research on CHIKV has demonstrated that interferons play an essential role during viral 
infection. Pretreatment of the human epithelial Hela cell line with type I or type II interferon 
inhibits viral replication and viral induced CPE (3). Adult C57Bl/6 mice are resistant to CHIKV 
infection whereas IFNAR
-/-
 mice die by day 3 p.i. and show wide viral dissemination and high 
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viral titers (4). IFNAR
-/-
 mice also show high serum levels of IFN and IFN on day2 p.i., which 
indicates that IFN is induced during CHIKV infection. Wild type mice infected with CHIKV do 
not show systemic production of IFN/, however it’s thought that local production of type I 
IFN is sufficient to protect wild type mice and limit viral dissemination. Sera from CHIKV 
infected human patients also have elevated type I interferon levels (5).  Type II interferon 
production does not appear to be as critical in controlling CHIKV infection, as IFN levels are 
not elevated in the sera of human patients and IFN-/- mice survive CHIKV infection (5).  
In order to understand how type I interferon protects against CHIKV infection, 
mechanistic studies have been done to describe the cell types necessary to produce and respond 
to type I IFN. Surprisingly, immature and mature monocyte-derived cDCs, isolated pDCs and 
monocytes are unable to produce type I IFN in response to CHIKV treatment. Instead, robust 
production of IFN can be detected from primary human foreskin fibroblasts and MRC-5 cells 
following CHIKV infection. This data suggests that hematopoietic cells do not produce type I 
IFN following direct stimulation with CHIKV and that fibroblasts may be responsible for the 
initial production of type I IFN. Bone marrow chimera studies have shown that type I IFNs act 
on non-hematopoietic cells in order to control CHIKV infection. In addition, search for viral 
sensors for CHIKV has revealed that both Cardif and MyD88 signaling pathways contribute to 
the control of CHIKV. In terms of the ISGs that mediate these antiviral activities against 
CHIKV, little is known. To start to address the mechanism by which type I IFNs mediate control 
of CHIKV infection, we turned our attention to the interferon stimulated gene ISG15. (5)  
 
Interferon Stimulated Genes 
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 Signaling through the IFNAR receptor leads to the induction of over 300 interferon 
stimulated genes (ISGs) (47). Many of the proteins that are induced by IFN play a role in 
pathogen recognition (PRRs) and act as transcription factors that amplify IFN production. 
Additional ISGs also have direct antiviral function. The effector activities of antiviral ISGs 
include a wide variety of functions, including but not limited to cytoskeletal remodeling, 
apoptosis induction, RNA regulation (splicing, editing, and degradation), and other post-
translational modifications (45).  
Some of the best known antiviral effectors include Mx GTPases, PKR, OAS and 
RNaseL, as well as ISG15. MxA monomers bind to viral nucleocapsid proteins, which leads to 
their degradation and limits viral replication. 2’, 5’ –oligoadenylate synthetase 1 (OAS1) is 
activated by viral dsRNA to generate 2’,5’ oligadenylates that subsequently bind to and activate 
RNaseL, which cleaves cellular and viral RNAs. PKR phosphorylates eukaryotic translation 
factor 2α (EIF2α) after binding to viral RNAs, which results in translation inhibition. Additional 
ISGs include the translation regulators IFIT1 and IFIT2 (IFN-induced protein with 
tetratricopeptide repeats), Viperin, APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic 
polypeptide), ISG20, and members of the tripartite-motif containing (TRIM) proteins such as 
TRIM1. Below, we discuss in greater detail the activity of ubiquitin like molecule ISG15. (45)  
      
ISG15 
 One of the most predominant genes induced by type I IFN is ISG15 (47, 48). ISG15 is a 
17kDa molecule that contains two ubiquitin-like domains connected by a peptide linker. Both 
domains of ISG15 contain approximately 30% identity to ubiquitin and assume a β-grasp fold 
secondary structure that is almost identical to that for ubiquitin (49). ISG15 is generated as a 
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propeptide that is processed by an unidentified cellular protease (possibly Ubp1) to reveal a 
conserved C-terminal LRLRGG diglycine motif that allows for ISG15 to be conjugated to target 
proteins (50, 51). Due to ISG15s structural similarity to ubiquitin, we will briefly review the 
activity of the ubiquitin family and ubiquitin like proteins (UBLs). 
 
Ubiquitin and UBLs 
 Ubiquitin is a 7kDa protein that forms isopeptide bonds with lysines of target proteins 
through a conserved LRLRGG C-terminal motif. Post-translational modification of proteins by 
ubiquitin can lead to a variety of functional consequences, dependent on the specific type or 
ubiquitin modification. The most commonly known function of ubiquitin is to target intracellular 
proteins to the proteasome through the formation of Lys48 poly-ubiquitin chains, which leads to 
protein degradation. Ubiquitin can also play an important role in many other cellular processes, 
including apoptosis, endocytosis, histone regulation and viral budding. (52, 53) 
 Ubiquitin like proteins (UBLs) share the same structural fold as ubiquitin and can also be 
conjugated to target proteins. Commonly known UBLs include SUMO-1 (small-ubiquitin-related 
modifier), Nedd8 (also known as RUB1 (related-to-ubiqutin-1)), Fat10, and several members of 
the autophagy pathway (Atg8, Atg12). Sumoylation (conjugation of proteins to SUMO-1) allows 
for protein localization around the nucleus and can also compete for ubiquitin binding sites to 
prevent ubiquitin mediated degradation. Nedd8 modifies subunits of the SCF (Skp1/cullin-1/F-
box protein) ubiquitin ligase family and is required for maximal ligase activity. Fat10 is also 
thought to compete for ubiquitin binding sites. Unlike ubiquitin, UBLs are not known to self-
conjugate, therefore act as monomeric conjugates. (54, 55)   
15 
 
Conjugation to target proteins for both ubiquitin and UBLs is mediated through an 
E1/E2/E3 enzymatic cascade. The C-terminus of the Ubl is activated via adenylation, allowing 
for the formation of a thioester bond with the Ubl activating enzyme E1. The ubiquitin like 
molecule is then transferred to a cysteine side chain of the conjugating enzyme E2, which can 
also bind to an E3 ligase protein. The E3 protein associates with the acceptor protein and allows 
for transfer of the ubiquitin moiety to the target protein. Modification of ubiquitin or UBLs to 
target proteins is reversible, as there exists several De-ubiquitinating and related enzymes. (55)  
 
The ISG15 conjugation cascade   
Similar to ubiquitin, ISG15 modification (ISGylation) of target proteins requires an E1, 
E2, E3 enzymatic cascade. UBE1L is thought to be the major E1 activating enzyme for ISG15, 
which is specific for ISG15 conjugation (56). The ubiquitin E2 protein UbcH8 appears to be the 
major E2 for ISG15 (57, 58). Herc5 is thought to be the most important E3 protein for 
ISGylation (59-61), although other additional E3s have been identified (e.g. Rsp5p, Efp) (57, 
62). In addition, ISG15 can be removed from targeted proteins by the deconjugating enzyme 
UBP43 (63). Unlike ubiquitin, ISG15 is not constitutively expressed. All members of the ISG15 
cascade, including UBP43, are induced following type I IFN stimulation. 
 
A role for ISG15 during viral infection 
The early induction and high levels of expression of ISG15 following IFN stimulation 
has led to the investigation into ISG15 as an antiviral molecule (Fig 1.1). Neonatal mice infected 
with the alphavirus Sindbis virus show >100 fold increase in ISG15 RNA as well as robust 
ISG15 conjugate formation (64-66). The first demonstration that ISG15 could function as an 
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antiviral molecule was overexpression of ISG15 through the use of a recombinant Sindbis virus 
construct. It protected IFNAR
-/-
 mice from Sindbis infection (66). Subsequent studies showed 
that ISG15
-/- 
mice were more susceptible to Sindbis virus (67). ISG15s role as an antiviral 
molecule is not limited to Sindbis infection, as ISG15
-/-
 mice are also susceptible to herpes 
simplex virus, gamma herpes virus, and influenza A and B viruses (67).  
  The ability of ISG15 to form conjugates appears to be critical for its antiviral role during 
Sindbis virus infection. UBE1L
-/-
 mice, which lack the ability to form ISG15 conjugates (68), 
have similar lethality as ISG15
-/-
 mice to Sindbis infection (69). ISG15
-/-
 mice infected with a 
recombinant Sindbis virus that expresses an unconjugatable form of ISG15 (LRLRAA) are not 
protected from viral induced lethality while the expression of wild type ISG15 (LRLRGG) 
protects ISG15
-/-
 mice (67, 69). The importance of ISG15 conjugation has also been 
demonstrated for other viral infections. UBE1L
-/-
 mice infected with influenza B phenocopy 
ISG15
-/-
 mice, with similar lethality and lung viral titers (70). Further support for the importance 
of conjugation comes from the immune evasion strategies employed by viruses. The NS1 protein 
of influenza B has been shown to directly inhibit ISG15 conjugate formation (56). OTU-domain 
containing viral proteins, such as the L protein of Crimean-Congo hemorrhagic fever virus 
(CCHFV) or the Nsp2 protein of Equine Arteritis virus (EAV), also reduce the level of ISG15 
conjugates (71). The ability of viruses to target ISGylation suggests that this is an important 
immune evasion strategy.  
 
ISG15 Function 
Although ISG15 has been shown to be an important antiviral molecule, the mechanism 
by which ISG15 inhibits viral infection is not well understood. Due to the apparent similarities 
17 
 
between ISG15 and ubiquitin as well as the demonstrated importance of ISG15 conjugation in 
vivo, current research has focused on determining the functional consequence of ISG15 
modification of target proteins. Over 200 potential targets of ISGylation have been identified 
using mass spectrometry. Targets of ISGylation take part in a number of cellular processes, 
including cell cycle, cell metabolism, and immune signaling pathways (72, 73). Viral proteins 
have also been shown to be targets of ISGylation (74, 75). A potential mechanism by which 
ISG15 targets such wide array of proteins with only one main E3 has been suggested. Herc5 has 
been shown to associate with polyribosmes, allowing for modification newly synthesized 
proteins (75). However, ISG15 modification appears to be specific, as not all newly translated 
proteins are ISGylated. 
ISG15 modification of target proteins has been suggested to cause either a loss or gain of 
function for the targeted protein. ISGylation of Ubc13 causes a reduction in polyubiquitinated 
TRAF6, which consequently leads to a decrease in NF-B activation (76). In addition, ISG15 
modification of filamin B disrupts its scaffold function which then downregulates the type I 
interferon-induced JNK signaling pathway (77). Conjugation of ISG15 to RIG-I has also been 
suggested to negatively regulate RIG-I mediated IFN induction (78). So far, modification of 
4EHP is the only reported gain of function for ISG15 (79). ISGylation of 4EHP enhances its cap-
binding activity which allows for inhibition of mRNA translation. Unlike ubiquitin, ISGylation 
has not been shown to directly lead to degradation of target proteins (80). 
Much less work has gone into studying the importance of free ISG15 during viral 
infection.  In vitro studies have demonstrated that expression of ISG15 interferes with budding of 
HIV-1 and Ebola virus like particles, although it remains unclear if this is conjugation 
independent (79, 81-83). Free ISG15 has also been shown to be released extracellularly and has 
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been suggested to have cytokine like activity. Non-conjugated ISG15 can be detected in the sera 
of humans treated with IFN as well as mice infected with certain viruses. PBMCs and non-
hematopoietic cell lines secrete ISG15 in response to IFN (84). Recombinant ISG15 has been 
shown to increase NK cell proliferation and lytic activity (85). Extracellular ISG15 has been 
shown to act as a neutrophil chemoattractant and can upregulate e-cadherin expression on 
dendritic cells (86, 87). Most recently, recombinant ISG15 in concert with IL-12 stimulation has 
been shown to upregulate IFNγ (88). Although ISG15 appears to have cytokine activity, a 
receptor for ISG15 has not been identified.  
Data that we have generated indicates that ISG15 is expressed following CHIKV 
infection. Nine day old wild type neonates were infected with CHIKV and ISG15 induction was 
assessed by qRT-PCR and western blot analysis. ISG15 mRNA at the site of infection is detected 
as early as 3hrs p.i. with peak levels obtained after 24hrs. Lung, liver and serum from nine day 
old wild type neonates show robust ISG15 induction and ISG15 conjugate formation by western 
blot analysis. The documented role for ISG15 in the host response to viral infection, including 
Sindbis virus infection, prompted us to evaluate its action in CHIKV pathogenesis.    
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Figure 1.1 Forms of ISG15 expression during viral infection. Detection of viral infection 
leads to upregulation of type I IFN, which mediates its activity through the induction of 
interferon stimulated genes (ISGs). The ubiquitin-like molecule ISG15, shown to play an 
important role during several viral infections, is upregulated along with members of the ISG15 
conjugation cascade: UbE1L (E1), Ubc8 (E2) and Herc5 (E3). This allows ISG15 to be 
conjugated to many different intracellular proteins. In addition, ISG15 can be found as a free 
form, both intra- and extracellularly. It is thought that extracellular ISG15 may have cytokine 
like activity via binding to an unidentified cell surface receptor. Figure generated by Nadia 
Giannakopoulos.  
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Figure 1.1 
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Abstract 
Chikungunya virus (CHIKV) is a re-emerging alphavirus that has caused significant disease in 
the Indian Ocean region since 2005. During this outbreak, in addition to fever, rash and arthritis, 
severe cases of CHIKV infection have been observed in infants. Challenging the notion that the 
innate immune response in infants is immature or defective, we demonstrate that both human 
infants and neonatal mice generate a robust type I interferon (IFN) response during CHIKV 
infection that contributes to, but is insufficient for, the complete control of infection. To 
characterize the mechanism by which type I IFNs control CHIKV infection, we evaluated the 
role of ISG15 and defined it as a central player in the host response, as neonatal mice lacking 
ISG15 were profoundly susceptible to CHIKV infection. Surprisingly, UbE1L
-/-
 mice, which 
lack the ISG15 E1 enzyme and therefore are unable to form ISG15 conjugates, displayed no 
increase in lethality following CHIKV infection, thus pointing to a non-classical role for ISG15. 
No differences in viral loads were observed between wild-type (WT) and ISG15
-/- 
mice, 
however, a dramatic increase in proinflammatory cytokines and chemokines was observed in 
ISG15
-/-
 mice, suggesting that the innate immune response to CHIKV contributes to their 
lethality. This study provides new insight into the control of CHIKV infection, and establishes a 
new model for how ISG15 functions as an immunomodulatory molecule in the blunting of 
potentially pathologic levels of innate effector molecules during the host response to viral 
infection.   
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Introduction 
Chikungunya virus (CHIKV) is a member of the genus Alphavirus, which are enveloped 
positive-strand RNA viruses transmitted by mosquitoes. It was first isolated in Tanzania in 1952, 
and reported to cause severe fever as well as myalgias, joint pain and rash within 2-5 days of 
infection (1, 2). Recently, CHIKV reemerged in Eastern Africa and has developed into a major 
epidemic in the Indian Ocean region. In 2006, an outbreak on the island of La Réunion resulted 
in the infection of approximately one-third of the inhabitants (3, 4). It has since spread to India 
and Southeast Asia with estimates of between 1-6 million people having been infected (5, 6). 
Concerns for the globalization of this virus has evolved given the continuation of this epidemic, 
the high serum viremia seen in infected patients, and mutations in the currently circulating strain 
of CHIKV that have allowed it to adapt to a more widely distributed mosquito vector (7). These 
concerns have been raised by both an increase in the number of foreign travelers contracting 
CHIKV and returning to both Europe and the United States, and by the possibility of spread by 
infected individuals, the latter being exemplified by the outbreak in Italy in 2007 and in Southern 
France in 2010 (5, 8, 9).  
 
The typical clinical presentation of adults infected with CHIKV includes fever, rash, 
arthralgias and severe myalgias. Infected neonates, however, display more severe disease, with 
symptoms including encephalopathy and cerebral hemorrhage, with a subset of these infants 
developing permanent disabilities (10). During the recent epidemic, it was reported for the first 
time that CHIKV-infected mothers can transmit the virus to their newborns during delivery, with 
a vertical transmission rate of approximately 50%, and in some instances infection resulted in 
mortality (10).  This age dependence of disease severity has also been reported for other 
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alphaviruses and can be reproduced in mouse models through the infection of suckling mice. 
Indeed, it has been shown that neonatal mice succumb to Ross River Virus (RRV) (11), Semliki 
Forest Virus (SFV) (12), Sindbis Virus (SINV) as well as CHIKV (13-15). There are likely 
several factors that contribute to this increased sensitivity in neonates, including alterations in the 
neonatal immune response.  
 
Regarding immune function in neonates, developmental delays have been described for 
the adaptive immune responses, however less is known about neonatal innate responses. While 
still controversial, many reports indicate that neonatal responses are diminished as compared to 
adults. For example, cord blood cells stimulated with TLR ligands produced low levels of TNFα, 
IL-1β, and IL-12 (16). Neonatal plasmacytoid DCs have also been shown to have impaired 
production of type I IFN in response to CpG stimulation (17).  It has been shown that LPS does 
not effectively activate IRF-3 dependent responses, including the production of IFNβ (18). The 
response to cytokines may also be impaired as there is evidence that STAT-1 recruitment 
following IFNγ stimulation is less efficient in neonatal than in adult leukocytes (19). Based on 
the critical role of type I IFN in the control of CHIKV infection (20), we considered the 
possibility that neonates may have a developmental delay in their type I interferon response, 
possibly contributing to their increased susceptibility to CHIKV infection and viral 
dissemination.  
In response to CHIKV infection, the production of type I IFNs is triggered by the 
engagement of the RLR pathway (20, 21). IFNs then stimulate the induction of hundreds of 
interferon stimulated genes (ISGs) and it is through these ISGs that IFNs mediate their effector 
function (22). One of the earliest ISGs induced following IFN stimulation is ISG15. ISG15 is a 
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17kDa protein that contains two ubiquitin-like domains connected by a proline peptide linker 
(23). Similar to ubiquitin, ISG15 can form conjugates with an array of intracellular host and viral 
proteins through the use of an E1 (UBE1L), E2 (UbcH8), and E3 (e.g., Herc5, Efp, HHARI) 
enzymatic cascade (24-28). Conjugation of ISG15 to target proteins has been suggested to cause 
either a gain or loss of function of the targeted protein, although the consequences of ISG15 
conjugate formation are not well understood (29-32). An unconjugated form of ISG15 can also 
be found in the sera of humans treated with IFN-βser as well as in virally infected mice (33, 34). 
The released form of ISG15 has been suggested to have cytokine like activity (35-37), however 
its role during an antiviral immune response has not been examined.   
 
The rapid induction of ISG15 following IFN stimulation has led to the identification of an 
antiviral role for ISG15 during infection. ISG15
-/-
 mice display increased susceptibility to SINV, 
herpes simplex virus-1 (HSV-1), gamma herpes virus (γHV68), influenza A and B viruses, and 
vaccinia virus (34, 38). ISG15
-/-
 mice infected with influenza B virus display a 2-3 log increase 
in lung viral titers as well as elevated cytokine and chemokine levels (34). The ability of ISG15 
to conjugate to target proteins appears to be essential for ISG15’s antiviral activity during certain 
viral infections, as UbE1L
-/-
 mice, which lack the ability to form ISG15 conjugates, phenocopy 
ISG15
-/-
 mice during both SINV and influenza B virus infection (39-41).  Further support for the 
importance of ISG15 conjugation during viral infection comes from the evolution of viral 
proteins that directly target ISG15 conjugate formation. Both the NS1 protein of influenza B 
virus and the E3L protein of vaccinia virus inhibit ISG15 conjugate formation, while OTU-
domain containing viral proteins, such as the L protein of Crimean-Congo hemorrhagic fever 
virus (CCHFV) or the Nsp2 protein of Equine Arteritis virus (EAV), and the SARS coronavirus 
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papain-like protease (SARS-CoV PLpro) exert both deubiquitinating and deISGylating activity 
(24, 38, 42, 43). Therefore, the antiviral activity of ISG15 has been thought to be conjugation 
dependent.    
 
Herein we demonstrate that despite an increased susceptibility of neonates to CHIKV 
infection, they produce robust levels of type I IFNs. While insufficient to completely control 
infection, IFNs participate in limiting the infection. We also show that ISG15 is induced during 
CHIKV infection and plays a critical role in protecting neonatal mice from viral induced 
lethality. Surprisingly, the mechanism of action by which ISG15 limits infection is independent 
of UbE1L mediated conjugation, as UbE1L
-/-
 mice displayed no phenotypic differences as 
compared to wild-type animals. Furthermore, ISG15 does not directly inhibit viral replication, as 
suggested by the similar viral loads in WT and ISG15
-/-
 mice. Instead, ISG15 appears to function 
as an immunomodulatory molecule in this model. These data demonstrate a novel role for ISG15 
during viral infection and suggests that prophylactic measures targeting the induction of IFN and 
ISG15 may help protect neonates during future CHIKV outbreaks.  
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Results 
CHIKV infected infants produce high levels of IFN and IFN-induced chemokines/ 
cytokines. 
Based on the increased severity of neonatal disease that has been observed during the recent 
epidemic of CHIKV, we assessed the inflammatory response of infants during the acute phase of 
CHIKV infection. Patients were recruited at the time of presentation in the emergency room and 
sera samples were collected and stored. CHIKV infection was confirmed by RT-PCR; and all 
patients were negative for anti-CHIKV IgG and IgM, indicating acute infection. We performed 
multi-analyte testing using Luminex technology, with a focus on inflammatory cytokines and 
chemokines. The inflammatory signature was compared to uninfected patients presenting to the 
emergency room for reasons unrelated to acute infection (e.g., broken bone). The intensity of the 
immune response in the infant vs. adult cohorts was compared. Non-parametric tests were used 
for the statistical analysis, and a false discovery rate (FDR) correction was applied to all p-values 
in order to adjust for multiple testing.  
We detected elevated levels of both IFNα and IFNγ in both groups of patients when 
compared to their respective control group (p < 0.005). Interestingly, both IFNα and IFNγ levels 
were more elevated in infants in comparison to adult patients (Fig. 2.1A). In addition, the 
chemokines/cytokines known to be induced by IFNs were highly expressed. These included 
CCL2, CCL4, CXCL9, CXCL10, IL-1Rα, IL-12p40/p70; and strikingly these analytes, with the 
exception of CXCL9, showed higher plasma concentrations in infants as compared to adult 
patients (Fig. 2.1B). Despite the clinical presentation including fever (Table S2.1), levels of the 
pyrogenic cytokines IL-1β and TNFα were not significantly elevated in patients when compared 
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to their controls; with only IL-6 being slightly upregulated in adult patient as compared to the 
control group (data not shown). Also of interest, while we observed marked induction of so-
called Th1 cytokines, such as IFNγ and IL-12p40/p70, there was no clear skewing toward a Th1 
response. In fact, we observed high levels of Th2 cytokines as well as Th17 cytokines (Fig. 
2.1C). Notably, these interleukins were upregulated as compared to healthy individuals, but were 
similarly expressed in the infected infant and adult groups. These data suggest that infants, while 
developing more severe manifestations of CHIKV, do indeed mount a robust acute response to 
infection. 
One potential caveat to this conclusion is that the viral load is higher in infants, possibly 
accounting for greater immune activation (median viral load in infants = 1.6 x 10
8
 RNA copies; 
median viral load in adults = 1.4 x 10
7
 RNA copies). Within the infant group, viral load 
negatively correlated with age, corroborating the observation that newborns are more susceptible 
to CHIKV induced disease (Fig. 2.2A). In adults, there was also an age-dependent trend with 
elderly harboring higher viral loads (Fig. 2.2A). Again this is consistent with the report that 
increased age is a risk factor for severe CHIKV disease (44). Next, we plotted plasma IFNα 
concentrations as a function of age.  These data demonstrate a strong negative correlation in 
infants, and followed the pattern seen for CHIKV titers (Fig. 2.2B). We found that IFNα levels 
correlated with viral loads in both group (Fig. 2.2C). To normalize for CHIKV titers, we 
separated each cohort in two groups (< global median : low viral load; and > global median : 
high viral load), in both groups the levels of IFNα were more elevated in infected infants than in 
infected adults (Fig. 2.2D). Furthermore, we performed univariate linear regression analysis to 
model the effect of infant status on plasma IFNα concentrations. Infants had higher IFNα 
concentrations compared to adults (RGM [95% CI] = 5.49 [3.16 - 9.53]; p<0.001). This effect 
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remained significant after adjustment for viral load (adjusted RGM [95% CI] = 3.44 (2.07 - 
5.70]; p<0.001). Thus for a similar viral load, infants produce more IFNα than adults. To 
represent associations between age, viral load, IFNα and the immune signature, we established a 
network plot of significant correlations (Fig. 2.2E). These data argue against infants being 
compromised in their response to CHIKV infection; however, we could not determine whether 
their IFN response was protective. To address this issue and to examine the mechanism of ISG 
mediated control of CHIKV, we exploited a recently described neonatal mouse model for 
studying infection (15). 
 
CHIKV infection in neonatal mice results in a robust type I interferon and 
proinflammatory cytokine response that is critical in controlling infection. 
Previously, we reported an age-dependent susceptibility to CHIKV infection in mice. Infection 
of 6 day old animals resulted in 100% mortality; 9 day old animals developed paralysis, with 
approximately 50% of the animals succumbing to infection; while by 12 days of age the mice 
became refractory to symptoms of severe disease and lethality (15). To compare our 
experimental mouse model of CHIKV infection to the response seen in human infants we 
assessed the IFN and proinflammatory responses in 8-9 day old mice. We first assessed the 
induction of the IFN response at the local site of infection by monitoring mRNA levels of 
2 
x 10
5
 PFU of CHIKV and the injection site was removed between 3–120 hrs post-infection. 
Increased expression of IFNβ mRNA could be detected as early as 3 hrs post-infection with peak 
levels being achieved at 16 hrs post-infection (Fig. 2.3A). Similar to IFNβ mRNA induction, 
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IRF7, Mx1 and ISG15 mRNA levels could also be detected as early as 3 hrs post-infection, with 
peak levels observed at 16 hrs post-infection (Fig. 2.3A).  Thus, at the site of infection, neonatal 
mice are able to induce IFNβ expression as well as a subset of known ISGs. Of note, IRF7 and 
Mx1 mRNA expression is indicative of signaling via the type I IFN receptor, suggesting that the 
production as well as reception of IFNαβ is intact in neonatal mice.  
We next assessed the systemic inflammatory response in this model. Similar to our 
findings in human infants infected with CHIKV, we observed a strong induction of IFNα and 
IFNγ in infected pups (Fig. 2.3B). Plasma concentration of CCL2, CCL4, CXCL9 and CXCL10 
were also elevated, however IL-12p70 was only modestly induced (Fig. 2.3C). Similar to the 
human data, a mixed Th1, Th2 and Th17 cytokine profile was observed with the induction of IL-
12, IL-5, IL-13, IL-15, and IL-17 (Fig. 2.3C). For all analytes, peak levels were seen 16–24h 
post-infection (Fig. 2.3). Notably, there were some differences seen between the murine neonate 
and human infant inflammatory profiles. Most interestingly, the mice displayed increased levels 
of the pyrogenic cytokines, including IL-1β, IL-6 and TNFα, which were not seen in our studies 
of human infants (Fig. 2.3C). While this may represent differences in pathogenesis, we believe it 
is more a reflection of the fact that the mice can be assessed within hours of viral inoculation, 
while the exact timing of the human infection is unknown. Overall, we find that the similarities 
between the mouse and human responses support the use of neonatal mice to study the response 
to CHIKV infection, and indicate that induction of IFNs, as well as the triggering of an ISG 
response, are both rapid and robust.  
Next, to confirm that endogenous IFN contributes to the control of CHIKV in neonatal 
mice, mice lacking subunit 1 of the type I IFN receptor (IFNAR
-/-
) mice were infected with 
CHIKV at 9 days of age. Consistent with our previous observations in adult mice (15), neonatal 
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pups lacking IFNAR were highly susceptible to CHIKV infection with 100% of the pups dying 
by day 2 post-infection (Fig. 2.4A). These pups developed a rapid, disseminated infection. 
Within 1 day of infection, the IFNAR1
-/-
 mice displayed viral loads at the injection site that were 
100-fold higher than that detected in WT controls. We also observed a striking increase in viral 
titers in the serum and multiple organs, including the brain, liver, and lung (Fig. 2.4B). These 
data indicate that endogenous IFN, while insufficient to protect mice, plays an important role in 
limiting CHIKV infection during disease pathogenesis in neonatal animals.    
 
Pre-treatment with Poly I:C prevents clinical disease and CHIKV induced death.  
Our results suggest that signaling via the IFNαβ receptor in neonatal mice results in the 
robust induction of at least a subset of ISGs and interferon-induced serum proteins (Fig 2.3), and 
that the absence of IFNAR results in exacerbated infection and rapid death (Fig. 2.4). One 
potential explanation is that neonates possess a developmental delay in their IFN-response that 
makes them susceptible to infection as compared to adult animals. It was therefore important to 
determine whether prophylactic innate immune responses could protect neonatal animals from 
CHIKV infection. To evaluate this question, we injected mice with 25 µg of poly I:C (pIC), a 
known inducer of type I IFN, and 1 day later mice were challenged with 2 x10
5
 PFU of CHIKV.  
At 7h post treatment with pIC, robust levels of IFNα were detected in the serum of neonatal mice 
(Fig. 2.5A).  Following CHIKV infection, mice were monitored daily for the development of 
symptoms and followed for lethality. Remarkably, 96% of the pIC treated mice survived, in 
contrast to only 40% of control mice (Fig 2.5B). Treatment with pIC also prevented CHIKV 
induced paralysis, with only 7% of the pIC treated mice developing paralysis during the course 
of the infection, as compared to 84% in the control group (Fig. 2.5C). Independent experiments 
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were performed using prophylactic treatment with 5000 U IFNβ. At both day 7 and day 11 post-
infection, mice receiving recombinant IFNβ displayed less severe disease, as compared to control 
PBS injected animals (Fig. S2.1), however, we did not see a statistical difference in survival, 
possibly due to the short half-life of IFNβ. To confirm that the protection induced by pIC was 
mediated by IFN, we repeated these experiments in IFNAR
-/-
 mice. As seen in Figure 2.5D, 
treatment of IFNAR
-/-
 mice with pIC resulted in no protection from lethality. These results 
indicate that the prophylactic engagement of the IFN receptor in neonates is able to induce a 
protective anti-viral response.  
ISG15 plays a significant role in the control of neonatal CHIKV infection.  
Interferons mediate their antiviral activity through the induction of ISGs, thus suggesting 
that investigation of the downstream effector molecules may offer additional insight into how 
neonates respond to CHIKV infection. The analysis of selected ISGs expressed at the site of 
infection revealed that ISG15 mRNA was rapidly and strongly induced during CHIKV infection 
(Fig. 2.3A). ISG15 is an ubiquitin-like molecule that conjugates to both host and viral proteins 
and has been previously shown to participate in the host response to SINV infection. An 
evaluation of ISG15 protein expression at the site of infection and within the serum confirmed 
that ISG15 and ISG15 conjugates were induced during CHIKV infection in WT mice (Fig. 
2.6B,C). As we previously described during neonatal SINV infection [45], the expression of 
ISG15 during CHIKV infection was also dependent upon intact IFN signalling since IFNAR
-/-
 
pups infected with CHIKV did not induce detectable levels of ISG15 (Fig. S2.2). To test the 
hypothesis that ISG15 is important in the control of CHIKV, we infected ISG15
-/-
 neonatal mice, 
comparing them to weight and age-matched WT control animals. Mice were followed daily for 
signs of illness and survival.  As reported above, infection of 9 day old WT neonatal mice 
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resulted in 58% lethality, with deaths occurring between days 10-13 post-infection. In contrast, a 
dramatic increase in lethality was observed in neonatal mice lacking ISG15, with greater than 
70% of the ISG15
-/-
 mice succumbing to infection within 3 days, and 100% of the mice dying by 
day 9 post-infection (Fig. 2.6A).  
It has been previously shown that WT mice become resistant to CHIKV induced lethality 
between 9 to 12 days of age, while mice lacking IFNAR1 remain susceptible to infection even as 
adults. Since ISG15 is an IFN-induced protein we next determined if its activity was age 
dependent. We infected either WT or ISG15
-/- 
mice at 11 or 12 days of age, or we infected adult 
mice between 6-8 weeks of age. By 11 days of age the WT mice had become largely resistant to 
CHIKV induced lethality with only 15% of the mice succumbing to infection (Fig. S2.3A). In 
contrast, we observed 100% lethality in the ISG15
-/-
 mice, although the onset of lethality was 
delayed, with the majority of the mice dying between 10 and 14 days post-infection. By 12 days 
of age the ISG15
-/-
 mice still showed clinical signs of disease, with a dramatic decrease in weight 
gain as compared to the WT controls (data not shown), but by this age only 20% of the ISG15
-/-
 
mice succumbed to the infection (Fig. S2.3B). Strikingly, adult ISG15
-/-
 mice, similar to WT 
controls, displayed no lethality and showed no signs of disease following CHIKV infection (Fig. 
S2.3C). Therefore, we conclude that ISG15 contributes to the control of CHIKV during neonatal 
infection, but redundant mechanisms are responsible for the control of CHIKV during adult 
infection.  
Since IFNs induce the expression of many ISGs, we next wanted to investigate if ISG15 
contributed to the protective anti-viral response established by prophylactic induction of type I 
IFN.  WT or ISG15
-/- 
mice were treated with 10 - 25µg of pIC and 1 day later challenged with 2 
x10
5
 PFU of CHIKV. Not unexpectedly, pretreatment with pIC offered protection to both WT 
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and ISG15
-/-
 mice. After pretreatment with 25μg of pIC, 14% of the ISG15-/- mice still 
succumbed to infection as compared to complete protection seen in the WT mice (Fig. 2.6D).  
Interestingly, only 50% of the ISG15
-/-
 mice were protected after pretreatment with 10μg pIC, as 
compared to 85% protection observed in the WT mice (Fig. 2.6E). These data support our 
observation that ISG15 is induced as part of the IFN response and that it plays an important role 
during CHIKV infection.  
ISG15 controls neonatal CHIKV infection independent of UbE1L mediated conjugation. 
We next investigated the mechanism by which ISG15 protects neonatal mice from 
CHIKV infection.  We had previously shown that the conjugation of ISG15 to target proteins is 
essential for the control of several viral infections (40, 41).  UbE1L is the only identified E1 for 
ISG15, and mice lacking UbE1L express free ISG15, but fail to form ISG15 conjugates (39). To 
establish a role for ISG15 conjugation, 9 day old UbE1L
-/-
 mice were infected with CHIKV. 
Surprisingly, UbE1L
-/-
 mice displayed no increase in lethality following CHIKV infection, and 
instead had a lethality curve similar to that observed in WT mice (Fig. 2.6A). Similarly, pIC 
treated UbE1L
-/-
 mice were protected to the level of WT controls (Fig. 2.6D, E). Western blot 
analysis on skin/muscle from the site of infection (Fig. 2.6B), as well as serum (Fig. 2.6C), was 
used to confirm that UbE1L
-/-
 mice generated no ISG15 conjugates during CHIKV infection, 
whereas WT mice showed robust conjugate formation. Additional organs (lung and liver) were 
also examined and no conjugates were detected in UbE1L
-/-
 mice (data not shown).  Thus, we 
demonstrate that the activity of ISG15 during CHIKV infection is UbE1L independent. 
In an attempt to provide additional evidence that unconjugated ISG15 was functioning in 
this model, we generated recombinant double subgenomic CHIK viruses that expressed either 
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WT ISG15 (CHIK- LRLRGG) or a mutant, non-conjugatable form of ISG15 (CHIK- LRLRAA) 
(Fig. S2.4A). This strategy was based on our previous report in which recombinant SINV 
expressing WT ISG15 (LRLRGG) rescued the increased lethality observed in the ISG15
-/-
 mice, 
while mutant ISG15 (LRLRAA) failed to compensate for the ISG15 deficiency (34, 40). Both 
CHIK-LRLRGG and CHIK-LRLRAA expressed ISG15 and displayed similar growth kinetics to 
CHIK-GFP in BHK cells (Fig. S2.4B, 4C). When we infected ISG15
-/-
 mice, however, neither 
CHIK-LRLRGG nor CHIK-LRLRAA was able to protect ISG15
-/-
 mice (Fig. S2.4D and data not 
shown). While these results do not allow us to confirm that the activity of ISG15 is independent 
of conjugation, they do suggest that the mechanism of action of ISG15 during SINV and CHIKV 
infection are distinct.   
To further evaluate the mechanism by which ISG15 functions during neonatal CHIKV 
infection we examined lymphocyte subsets and viral titers in WT, UbE1L
-/-
 and ISG15
-/-
 mice. 
We detected no significant differences in the lymphocyte subsets of naïve neonatal WT, UbE1L
-
/-
 and ISG15
-/-
 mice (Table S2.2). Similar results have been observed in both naïve and pIC 
stimulated adult mice (39, 45). These data suggest that differences in starting cell populations do 
not account for the increase in lethality observed in ISG15
-/-
 mice.  We next assessed viral titers 
on days 1 and 2 post-infection. As expected, UbE1L
-/-
 mice displayed similar viral loads in 
multiple tissues when compared to WT mice at days 1 and 2 post-infection (Fig. 2.7A and B). 
Given that the ISG15
-/-
 pups infected at 9 days of age displayed a dramatic increase in lethality, 
with kinetics similar to that observed in the IFNAR
-/-
 mice, we expected to detect increased viral 
titers in the ISG15
-/-
 mice. To our surprise, at 1 day post-infection the serum and tissues analyzed 
from the ISG15
-/-
 mice contained viral titers that were similar to those obtained in both UbE1L
-/-
 
and WT mice (Fig. 2.7A). This was in striking contrast to the 2-3 log increase in viral loads 
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detected in the IFNAR
-/-
 mice 1 day post-infection (Fig. 2.4B). By 2 days post-infection, just 
prior to when the majority of ISG15
-/-
 mice succumb to infection, we still detected similar viral 
loads between WT, UbE1L
-/-
 and ISG15
-/-
 mice in the analyzed tissues (Fig. 2.7B).  Based on 
these data we suggest that ISG15 may not be playing a direct anti-viral role, but instead may be 
acting via an unexpected mechanism of regulating host sensitivity to the viral induced immune 
response.  
Since our evaluation of human infants and neonatal mice demonstrated that CHIKV 
infection induces a robust proinflammatory cytokine and chemokine response (Fig. 2.1 and 2.3), 
we investigated the impact of ISG15 deficiency on this host response. IFNβ mRNA levels were 
induced in the skin of WT, UbE1L
-/-
 and ISG15
-/-
 mice at 24 and 48hrs post infection with no 
significant differences noted between the three strains of animals (Fig. 2.8A). Serum from WT, 
UbE1L
-/-
 and ISG15
-/-
 mice collected at 1 or 2 days post-infection were analyzed for IFNα as 
well as proinflammatory cytokines and chemokines. Analysis of IFNα serum levels also revealed 
no significant differences between WT, ISG15
-/-
, and UbE1L
-/- 
mice at either 24 or 48 hrs post-
infection (Fig. 2.8B). Despite similar viral loads and type I IFN induction, the ISG15
-/-
 mice 
displayed elevated levels of TNFα, IL-1β and IL-6 as compared to both the WT and UbE1L-/- 
mice (Fig. 2.8C). Interestingly the levels of these three pyrogenic cytokines in the ISG15
-/-
 mice 
were comparable to what was observed in the IFNAR
-/-
 pups, despite the latter having 
significantly higher viral loads. ISG15
-/-
 mice also displayed elevated chemokine levels, 
including CCL2, CCL3 and CCL5 (Fig. 2.8C). Therefore, although viral titers between ISG15
-/-
, 
UbE1L
-/-
 and WT mice are similar, ISG15
-/-
 neonates display an exaggerated proinflammatory 
cytokine response to CHIKV infection. Together, these data indicate that ISG15, independent of 
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UbE1L mediated conjugation, is contributing to the control of CHIKV infection by blunting 
potentially pathologic levels of innate effector molecules.  
Elevated pro-inflammatory cytokine levels likely contribute to the increased lethality seen 
in CHIKV infected neonatal ISG15
-/-
 mice. 
 We hypothesized that the exaggerated cytokine response displayed in ISG15
-/-
 mice 
during CHIKV infection could contribute to the increased lethality in ISG15
-/-
 compared to WT 
and UbE1L
-/-
 mice. The levels of TNFα observed were similar to what has been previously 
reported in adult models of LPS induced septic shock (46, 47) as well as neonatal Sindbis virus 
infections (48), where mice are thought to die from a cytokine storm. Consistent with a cytokine 
storm phenotype, no striking differences in histology (H&E) were found between the three 
genotypes, although necropsy analysis revealed that ISG15
-/-
 had more severe blood vessel and 
airway injury than WT and UbE1L
-/-
 mice (data not shown). To support our findings, we also 
performed a blood chemistry analysis on serum collected on day 2 post CHIKV infection from 
WT, UbE1L
-/-
 and ISG15
-/-
 neonatal mice. Blood chemistry analytes can be used to assess the 
function of the liver, kidneys, heart, pancreas and other organs. Alteration in blood analyte levels 
(ALT, AST, BUN and Creatinine) can be an indication of multiple organ dysfunction syndrome 
(MODS) that can also occur during septic shock (49-51). Preliminary data suggests that WT and 
UbE1L
-/- 
mice do not display changes in blood analyte levels compared to PBS treated mock 
controls (Figure S2.5). In contrast, we observed elevated levels of ALT, AST, and BUN in 
CHIKV infected ISG15
-/-
 mice compared to WT and UbE1L
-/-
 mice (Figure S2.5). We also 
observed decreased levels of glucose in ISG15
-/-
 mice. No difference was observed in Creatinine 
levels. This data is consistent with our cytokine data (Figure 2.8C) and suggests that CHIKV 
infected ISG15
-/-
 may suffer from multiple organ dysfunction. We have also generated 
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preliminary data that indicates that pre-treating neonatal ISG15-/- mice with a blocking TNFα 
antibody delays CHIKV induced lethality (data not shown). Altogether, our data supports the 
hypothesis that elevated cytokine levels contributes to increased lethality in CHIKV infected 
neonatal ISG15
-/-
 mice. 
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Discussion 
The ongoing epidemic of Chikungunya virus occurring in the Indian Ocean region has 
highlighted how little we understand about the pathogenesis of this virus. Epidemiological 
studies have provided the first documentation of vertical transmission, as well as providing 
detailed information about the severity of disease and long term sequelae (4, 52-54).  One 
important finding from these studies concerns the increased susceptibility of neonates and infants 
to severe forms of Chikungunya disease (10, 44, 55). In this study, we evaluated the response of 
infants to CHIKV infection using data from both human samples collected during the La 
Réunion outbreak, as well as taking advantage of a newly described mouse model of infection. 
Our results show that human infants and murine neonates mount a robust innate immune 
response to CHIKV infection, which includes the induction of type I IFNs, several cytokines and 
chemokines, and the induction of at least a subset of IFN induced genes, including ISG15.  We 
establish a role for ISG15 in the pathogenesis of CHIKV infection with an absolutely essential 
role in the neonatal response to infection. Moreover, and to our surprise, the reported data 
suggest that ISG15 acts independently of UbE1L mediated conjugation and rather than exerting a 
direct anti-viral role, it appears to be implicated in limiting an exaggerated inflammatory 
response.  
In general, neonates are more susceptible to microbial and viral infection. This 
vulnerability has been explained by two principal mechanisms: broader tropism of the infectious 
agent or a defective host response. Regarding the latter, many argue that neonatal susceptibility 
to infection is due to a delayed or weaker immune response (16, 56). Factors contributing to this 
include delays in immune system maturation, decreased expression of activation receptors, or 
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distinct regulation of signaling pathways in neonatal vs. adult immune cells.  Since the type I 
IFN response is critical for controlling CHIKV infection (15, 20), we hypothesized that neonates 
may have a defect in their ability to either produce and/or respond to IFN. Instead, we observed 
that the production of type I IFN was intact in both human infants and mouse neonates.  
Furthermore, the relative level of IFN produced in infants was higher than the responses 
observed in adult human patients, even when viral load was normalized between the two patient 
groups (Fig. 2.1). These data indicate that neonates do not have a defect in their ability to 
produce type I IFN during CHIKV infection, and may actually be hyper-responsive. Very little 
has been reported on the signaling through RLRs or other viral sensors in neonates. Most 
previous work has supported the notion that signaling through TLR receptors, including TLR4, 
are diminished in neonates (57, 58). However, one study did find that neonatal mice exhibited 
increased lethality following LPS treatment, due in part to an exaggerated pro-inflammatory 
cytokine response as compared to adult mice (59).  Future work is needed to characterize 
differences that may exist between neonatal and adult RLR signaling. 
We also demonstrate that neonates can respond to the IFN that is produced. In both 
human infants and in neonatal mice, several known IFN-induced chemokines and cytokines were 
upregulated during the course of infection (Fig. 2.1-3). These results suggest that the ability to 
respond to IFNs was at least partially intact. These observations were confirmed by 
demonstrating the greater susceptibility of neonatal mice lacking expression of the type I IFN 
receptor (Fig. 2.4); notably, the kinetics of viral replication and death were massively accelerated 
as compared to age-matched WT controls. Additionally, we demonstrate that the prophylactic 
exposure to an interferon-inducing adjuvant protected animals from challenge with lethal doses 
of CHIKV (Fig. 2.5).  
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To provide insight into the mechanism by which IFN participates in the host response to 
CHIKV infection, we evaluated the role of ISG15, an anti-viral host protein that has previously 
been shown to be important in the control of several viruses, including SINV (34). We found that 
ISG15
-/-
 mice were more susceptible to CHIKV infection, demonstrating a dramatic increase in 
lethality as compared to WT mice (Fig. 2.6A).  Moreover, ISG15 played a critical role in pIC 
induced protection of mice in a prophylactic setting (Fig.2.6D, 2.6E). While OAS has previously 
been shown to inhibit viral replication when over-expressed in vitro (60), to our knowledge our 
data is the first in vivo demonstration of an IFN effector molecule having activity against 
CHIKV.   
Most importantly, the results from our current study indicate that ISG15 is regulating 
CHIKV pathogenesis by a unique mechanism of action.  First, we demonstrate that ISG15 
regulates CHIKV infection independent of UbE1L mediated conjugation. This is in contrast to 
both influenza virus and SINV infection, where the anti-viral activity of ISG15 is dependent 
upon ISG15 conjugation and abrogated in UbE1L
-/-
 animals (40, 41).  The protection mediated 
by ISG15 during pIC prophylaxis also appeared to be UbE1L independent, as UbE1L
-/-
 mice 
displayed survival curves similar to WT mice (Fig. 2.6D, 2.6E). These results suggest that the 
non-classical function of ISG15 is at work both during acute viral infection and in the pIC 
induced protection seen in our mice.  UbE1L is the only known E1 for the ISG15 pathway, and 
our analysis of the UbE1L
-/-
 mice revealed no conjugation activity post-infection (Fig. 2.6 and 
(39)).  Therefore the actions of ISG15 during CHIKV infection are likely to be independent of 
conjugation, and mediated by free ISG15.  One alternative explanation may be the involvement 
of a second E1, as has been identified for the ubiquitin pathway (61). Second, it appears that 
during CHIKV infection, ISG15 is not functioning as a direct antiviral molecule.  In both the 
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influenza and SINV models, the increase in lethality was accompanied by a dramatic increase in 
viral loads (34, 38, 41). In contrast, during CHIKV infection, ISG15
-/- 
mice did not show an 
increased CHIKV burden (Fig. 2.7). Instead, we noted a significant elevation of several 
proinflammatory cytokines and chemokines in the ISG15 deficient mice (Fig. 2.8). Therefore, as 
opposed to having direct antiviral activity, it appears that ISG15 modulates the immune response 
during CHIKV infection. Finally, in contrast to what was previously reported for control of 
SINV infection (34), a recombinant CHIKV expressing ISG15 was unable to rescue neonatal 
ISG15
-/-
 mice from viral induced lethality (Figure S4). The inability to rescue the ISG15
-/-
 
phenotype may be due to insufficient expression levels of ISG15; the timing of ISG15 expression 
may be delayed as compared to WT mice; or may in fact indicate that ISG15 expression is 
required in an uninfected cell.  Since we detect no differences in viral load, and instead observed 
increased cytokine levels in the ISG15
-/-
 mice, we favor this later possibility. Further analysis 
into the precise mechanism by which ISG15 regulates the host response to CHIKV should 
provide additional insight into this issue. Together, our data suggest a novel mechanism for 
ISG15, which is likely to be independent of conjugation and extrinsic to virally infected cells.      
The precise mechanism by which ISG15, independent of UbE1L mediated conjugation, 
contributes to the control of viral infection is currently unclear.  The most intriguing difference 
we have noted to date is the increased cytokine responses in the mice lacking ISG15 (Fig. 2.8).  
As noted above, while we cannot formally exclude the possibility of another E1 functioning in 
this system, it seems most likely that free, unconjugated ISG15 mediates the activity during 
CHIKV infection.  Free ISG15 is found within the cell, but interestingly it may also be secreted 
by a still undefined mechanism (33). Previous work has shown that unanchored ISG15 can 
associate non-covalently with proteins (i.e. independent of conjugation). For example, the NS1 
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protein of influenza B virus can non-covalently bind ISG15, thereby inhibiting its interaction 
with UbE1L and blocking conjugation of target proteins (24). The over-expression of ISG15 has 
also been shown to disrupt Nedd4 ligase activity and inhibit Ebola virus VLP release (62, 63). 
Recent research within the ubiquitin field has described a role for unanchored polyubiquitin 
chains, shown to regulate TRAF6 function, as well as promote RIG-I dimerization and signaling 
(64, 65). It is therefore possible that intracellular, unanchored ISG15 interacts non-covalently 
with members of an innate immune signaling pathway to regulate cytokine and chemokine 
production or other host response pathways. Alternatively, released ISG15 could be contributing 
to the phenotype seen during CHIKV infection. Indeed, the 17 kDa form of ISG15 is released 
into the serum in both WT and UbE1L
-/- 
mice during CHIKV infection (Fig. 2.6). Released 
ISG15 has been reported to function as an immunomodulatory molecule, increasing NK cell 
proliferation and lytic activity, acting as a neutrophil chemoattractant, and upregulating E-
cadherin expression on dendritic cells (35-37). Released ISG15 could function as in 
immunomodulatory cytokine by signaling through a receptor to regulate the cytokine response or 
through its ability to function as a chemoattractant. In order to characterize these effects in 
greater detail, a receptor for ISG15 must be identified. Future studies evaluating these 
possibilities will be required in order to further define the mechanism by which ISG15 is 
contributing to the host response to CHIKV.   
Although we do not understand mechanistically why ISG15
-/-
 mice display elevated 
cytokine levels during CHIKV infection, our data indicates that this cytokine increase is 
biologically significant. During neonatal Sindbis virus infection, mice are thought to succumb to 
infection due to a cytokine storm (48). The lack of alterations in major organ histology and the 
levels of TNFα produced in our CHIKV model are consistent with what has been described for 
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SINV. We also provide additional evidence that CHIKV infected ISG15
-/-
 mice may suffer from 
multiple organ dysfunction syndrome (MODS), another readout for septic shock, as indicated by 
altered blood chemistry levels (Fig. S2.5) (49). Therefore, elevated cytokine production 
contributes to the increased lethality in ISG15
-/-
 mice. Cytokine production may be a relevant 
readout for future functional studies to understand the mechanism of ISG15 mediated host 
regulation. 
In conclusion, we have demonstrated that neonates are capable of producing type I 
interferon in response to CHIKV, which serves to limit viral infection though remains 
insufficient to clear the virus. We have demonstrated a critical, age-dependent role for ISG15 
during neonatal infection. We have also characterized the mechanism of ISG15 activity, 
revealing a novel mechanism for ISG15, independent of UbE1L mediated conjugation, and 
functioning as a putative immunomodulator of proinflammatory cytokines. The ability of pIC to 
protect neonatal mice against CHIKV infection suggests that manipulation of the IFN signaling 
pathway, and perhaps the induction of ISG15, may be an appropriate therapeutic target for 
combating CHIKV infection. 
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Materials and Methods 
 
Ethics Statement 
All human studies were approved by the Committee for Clinical Research at the Institut Pasteur, 
project number RBM 2009-23, on July 9, 2009. Written informed consent was obtained from the 
study participants or legal guardians.  For mouse studies at the Institut Pasteur and at Washington 
University, the principles of good laboratory animal care were carried out in strict accordance 
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health and following the International Guiding Principles for Biomedical 
Research Involving Animals.  The protocols were approved by the Animal Studies Committee at 
Washington University (#20090287) and the Institutional Committees on Animal Welfare of the 
Institut Pasteur (OLAW assurance # A5476-01). All efforts were made to minimize suffering. 
  
Human Study 
Retrospective study on patients who presented to the emergency  or pediatric service of the 
Groupe Hospitalier Sud Réunion, Saint Pierre, La Réunion, France from January 2006 through 
May 2006.  Sera samples were collected and stored at -80°C.  CHIKV infection was confirmed 
by RT-PCR.  All patients were negative for anti-CHIKV IgG and IgM as assessed by 
immunocapture Elisa.  The control cohort consisted of patients that presented to the orthopedic 
chirurgy or infant chirurgy service of the Groupe Hospitalier Saint Pierre before the epidemic.  
These patients were IgG, IgM and RT-PCR negative for CHIKV. Data from adult patients were 
previously reported (20), but are shown here for comparison to data from infected neonates. 
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Virus   
The preparation of CHIKV from clinical samples has been previously described (66). CHIKV 
(06.21) strain was isolated during the epidemic in La Réunion and then propagated three time on 
C6/36 mosquito cells to generate a stock (6x10
7
 PFU/mL) that was used in all experiments. 
Recombinant CHIKV strains. The generation and characterization of a recombinant double 
subgenomic CHIKV virus expressing GFP, CHIKV-LR 5’ GFP, has been previously described 
(67). Recombinant CHIKV expressing ISG15 were generated as follows. 
(i) ISG15 LRLRGG. Nucleotides 1 to 465 of murine ISG15 were PCR amplified using a 5’ 
primer that introduced an AscI restriction site and a 3’ primer containing GGT GGG 
TAA sequence and a PmeI site. 
(ii) ISG15 LRLRAA. Nucleotides 1 to 465 of murine ISG15 were PCR amplified using a 5’ 
primer with an AscI restriction site and a 3’ primer containing GCG GCG TAA sequence 
and a PmeI site.  
The correct sequence for each virus was confirmed. Generation of recombinant ISG15 viruses 
was previously described (68). Viral stocks were generated by in vitro transcription of linearized 
cDNA templates, followed by transfection of the transcripts with Lipofectamine (Invitrogen) into 
BHK cells.  Supernatants were harvested 48 hrs post transfection and viral titers were determined 
by plaque assay as described below. To examine growth characteristics of the recombinant 
viruses, BHK cells were infected at a multiplicity of infection (MOI) of 1.0 and viral titers were 
measured at various times post-infection. To determine the expression of ISG15 from 
recombinant viruses, BHK cells were infected at an MOI = 1.0 and at various times post-
infection total cell lysates were harvested and ISG15 expression was analyzed by Western blot 
analysis. 
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Mice  
Experiments in mice were carried out at both the Institut Pasteur, Paris, France and at 
Washington University School of Medicine, St. Louis, Missouri, using the identical CHIKV viral 
stock described above.  Infection of 9 day old pups with 2 x 10
5
 PFU subcutaneously (s.c.) 
resulted in approximately 50-60% lethality in WT mice at both locations.  For experiments 
carried out at the Institut Pasteur, eight day old C57BL/6 litters were obtained from Charles 
River laboratories (France). For experiments carried out at Washington University, mice were 
maintained at Washington University School of Medicine in accordance with all federal and 
University guidelines. ISG15
-/-
 mice were provided by Dr. Ivan Horak and Dr. Klaus-Peter 
Knobeloch. UbE1L
-/-
 mice were provided by Dr. Dong-Er Zhang. The generation of both the 
ISG15
-/-
 and UbE1L
-/-
 mice has been previously described (39, 45).  C57BL/6, IFNαβ receptor 1 
(IFNAR1
-/-
), UbE1L
-/-
 and ISG15
-/-
 mice, all on the C57BL/6 background, were bred and 
maintained in our mouse colony.  Congenic SNP analysis (Taconic laboratories) of UbE1L
-/-
 and 
ISG15
-/-
 mice confirmed that these mice were fully backcrossed, with 99.93% and 99.72% 
identity to C57BL/6 mice, respectively. For neonatal experiments mice were infected between 9 
and 12 days of age as indicated.  Litters were weight matched at the initiation of the experiments.  
For adult experiments, mice were infected between 6-8 weeks of age and were age and sex 
matched within experiments. 
 
Viral studies   
For neonatal experiments using the clinical isolate of CHIKV, 9 day old pups were infected with 
2.0 x 10
5
 PFU CHIKV in 20-30 µL of PBS by injection subcutaneously (s.c.) into the right flank.  
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Infected mice were followed daily for weight gain, signs of disease, and lethality for 21 days 
post-infection.  Paralysis was scored as an inability or long delay (>5s) to return and land on its 
feet when flipped on its back. For experiments with adult mice, 6-8 week old mice were infected 
as outlined above and followed for daily weight loss and lethality.  For experiments utilizing the 
recombinant CHIKV clones, 6 day old pups were infected with 3 x 10
5
 PFU of the indicated 
recombinant virus diluted in 30 μL of PBS by s.c. injection into the right flank.  Viral titers were 
determined in organs harvested at the indicated days post-infection. Organs were harvested into 1 
ml of DMEM without fetal bovine serum and homogenized with 1.0 mm diameter zirconia-silica 
beans at 3,200 rpm for 1 minute with a MagnaLyzer prior to plaque assay on BHK cells, protocol 
modified from (69). Serial dilutions of organ homogenates in DMEM with 1% FBS was added to 
BHK cells (6x10
5
 cells for 6 well plates) and incubated for 1hr at 37⁰C. An agar overlay was 
then added to the cells and incubated for 28hrs at 37⁰C. Plates were fixed with 1% formaldehyde 
(>30min at room temperature), agar plugs were removed and plaques were visualized using a 1% 
crystal violet solution.   
 
Poly I:C prophylactic treatment studies   
Eight day old mice were injected intraperitoneally (i.p.) with 10-25µg of high molecular weight 
polyI:C (Invivogen).  Twenty-four hours later, mice were challenged with 2 x 10
5
 PFU CHIKV 
s.c. Mice were monitored daily for the development of symptoms and followed for lethality as 
described above.  
 
Cytokine and blood chemistry analysis  
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Sera were harvested and conserved at -80ºC for analysis. Human cytokines were measured by 
Luminex (25 plex kits, Biosource, Invitrogen) following manufacturer’s instructions. Human 
CXCL10 was re-titrated by ELISA (human quantikine ELISA kit, R&D). Mouse sera were 
obtained after coagulation of blood in T-MG tubes (Terumo).  Mouse IFNα levels were 
quantified by ELISA (PBL biomedical) and other cytokines were measured using Luminex 
technology with either the 32 plex from Millipore (MPXMCYTO-70X) or by customized 10 
plex from Biorad. Blood chemistry analytes were processed by the DCM core facility at 
Washington University in St. Louis. 
 
qRT-PCR for quantification of viral load and IFN mRNA  
For determination of patient viral load, total nucleic acid extraction was performed on sera in a 
MagNa Pure automate using the Total Nucleic Acid Kit (Roche Diagnostics). CHIKV RNA was 
detected with specific taqman probes using a one step RT-PCR (Master RNA hybridization 
probes, Roche) performed on a Chromo 4 machine (Biorad).  The 20μL reaction mix contained 
2μL of extracted RNA, 7.5μL of LightCycler RNA Master Hyb-Probe, 3.25 mmol/L Mn2 , 450 
nmol/L CHIKV-forward primer, 150 nmol/L CHIKV-reverse primer, 150 nmol/L CHIKV Probe 
(5 6-carboxyfluorescein-3 TAMRA) (TibMol-Biol). The thermal cycling consisted of a reverse 
transcription at 61 °C for 20 min followed by 45 cycles at 95 °C for 5 s and 60 °C for 15 s. The 
fluorescence was measured at 530 nm. CHIKV load is measured using a synthetic RNA 
calibrator (70). CHIKV-rev CCAAATTGTCCGGGTCCTCCT; CHIKV-forw 
AAGCTCCGCGTCCTTTACCAAG; Probe: Fam-CCATGTCTTCAGCCTGGACACCTTT-
TAMRA.  
 
58 
 
For mouse studies, skin tissue was harvested at the site of infection on days 1 and 2 post-
infection.  Tissue was snap frozen in liquid nitrogen and then homogenized in RLT+ with 0.04M 
DTT, and RNA was extracted with the Qiasymphony robot (Qiagen) with a protease step and a 
DNase step.  The quality and quantity of RNA was evaluated with the Agilent technology, with 
the RNA integrity number between 8 and 9.5.  Reverse transcription was performed with random 
primers (Roche) using Superscript enzyme (Invivogen). cDNA for murine IFN-β and ISG15 
were detected using Applied Biosystem Taqman probes (Mm00439546-s1, Mm01705338-s1).  
To analyze the relative fold induction of mRNA, GAPD expression levels were determined in 
parallel for normalization using the CT method.  
 
Western blot analysis 
Nine day old mice were infected with 2x10
5 
PFU CHIKV. Tissue homogenates as well as serum 
samples were subjected to protein electrophoresis on a 12% Tris gel. The gel was transferred to a 
polyvinylidene fluoride membrane and probed for ISG15 expression using a rabbit anti-ISG15 
polyclonal serum (1:5000) as previously described (68). The membrane was then developed with 
a horseradish peroxidase (HRP)-conjugated goat anti-rabbit antiserum (Jackson 
Immunoresearch, West Grove, Pennsylvania) diluted 1:200,000. For loading controls, the same 
blot was re-probed with anti-β-actin mAb (clone AC-74; Sigma) and then developed with a HRP 
conjugated goat anti-mouse antibody (Jackson Immuno-Research). All blots were developed 
with chemiluminescent reagent (Millipore).     
 
Flow Cytometry  
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Spleens were harvested from naïve nine day old WT, UbE1L
-/-
 and ISG15
-/-
 mice (12 mice per 
strain). Lymphocyte subsets were stained using the following cell surface markers: CD3, CD4, 
CD8, NK1.1, CD19, F4/80 and Gr1. Data is represented as percent of the total cell population 
and Kruskal-Wallis test was used to compare the three genotypes.  
 
Statistical analysis  
Data were analyzed using the Prism software (Graphpad software). The OMNIVIZ statistical 
platform (BioWisdom, Cambridge, UK) was used to perform comparisons among data sets using 
nonparametric tests (Mann-Whitney U-test) and false discovery rate (FDR) procedures, a 
permutation-based method to correct for the increased probability of obtaining a false positives 
among all significant tests (71). Differences were considered significant if p < 0.05. 
 
List of accession numbers in GenBank 
IFNγ: NM_008337, CCL2: NM_011333, CCL4: NM_013652, CXCL9: NM_008599, CXCL10: 
NM_021274, IL12: NM_008352, IL1Rα: NM_001039701, IL4: NM_021283, IL5: NM_010558, 
IL13: NM_008355, IL15: NM_008357, IL17: NM_010552, IFNβ: NM_010510, IRF7: 
NM_016850, Mx1: NM_010846, ISG15: NM_015783, IL1β: NM_008361, IL6: NM_031168, 
TNFα: NM_013693, IFNAR1: NM_010508, UbE1L: NM_023738. 
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Figure 2.1. Serum concentration of IFN and IFN-induced chemokines is higher in CHIKV 
infected infants as compared to adults. Patient sera were obtained from acute CHIKV infected 
adults (age = 16-86 years) and infants (age = 2-5 months). Age matched controls from La 
Réunion were tested. Chemokines / cytokines were measured using a Luminex assay. (A) IFNα 
and IFNγ levels; (B) IFN-induced molecules; and (C) Lymphocyte cell derived cytokines are 
shown. Whisker-box plots are shown (line indicates median; boxes represent first and third 
quartile; and bars define range). Mann-Whitney U-test was performed using a false discovery 
rate (FDR) procedure for generating corrected p-values. Comparisons were made between 
CHIKV patients versus their control cohort (in black); as well as adult versus infant patients (in 
red). ** indicates p<0.005, * indicates p<0.05. IFN data from adult patients were previously 
reported (5), but are shown here for comparison to data from infected neonates.  
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Figure 2.1 
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Figure 2.2. Higher serum IFNα in infants is not explained by differences in viral load. (A-
C) Correlations between viral load vs. age; IFNα vs. age; and IFNα vs. viral load were evaluated. 
CHIKV infected infants are represented by blue squares; CHIKV infected adults are represented 
by red circles. Lines indicate linear regression and Spearman correlation (rs) values are shown. 
(D) Each group was divided into two subgroups (<median: low viral load or >median: high viral 
load; Median = 4.8x10
7
) and statistic are represented (Mann Whitney test) (E) For analytes 
identified in Figure 1 that showed a correlation with viral load, IFN or age are plotted in a 
network array, illustrating the correlations identified in neonatal vs. adult individuals. Connecting 
lines indicate Spearman correlation (rs) values; positive correlations in red and negative 
correlations are depicted in blue. IFN data from adult patients were previously reported (5), but 
are shown here for comparison to data from infected neonates. 
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Figure 2.2 
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Figure 2.3. Neonatal mice mount a robust IFN and pro-inflammatory cytokine/chemokine 
response following CHIKV infection. Nine day old C57BL/6 mice were injected s.c. in the 
right flank with CHIKV. (A) The skin at the site of infection was harvested at the indicated times 
post infection and IFNβ, IRF7, Mx1 and ISG15 gene expression was evaluated by qRT-PCR. 
The ΔCt was calculated using GAPD as a reference gene. At various time points, sera was 
harvested and tested for (B) IFNα by ELISA and IFNγ using Luminex. (C) Serum cytokines and 
chemokines were also analyzed using Luminex. Each graph represents 2-3 independent 
experiments with 3 mice per experiment.  
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Figure 2.3 
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Figure 2.4. Endogenous Type I IFN is required for the control of neonatal CHIKV 
infection. WT and IFNAR1
-/-
 mice were infected at 9 days of age with 2x10
5
 PFU CHIKV s.c. 
(A) Mice were monitored for lethality for 21 days with data displayed as Kaplan-Meier curves. 
(B) Tissue and sera were collected on day 1 post-infection and viral titers were determined using 
a standard plaque assay. Mann-Whitney statistical comparison of wild type and IFNAR1
-/-
 viral 
titers are shown where * indicates p<0.05, ** p<0.005 and *** p<0.0005, and vertical bars 
represent standard error of the mean.  
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Figure 2.4 
 
 
 
 
 
 
 
 
 
 
 
69 
 
Figure 2.5. Adjuvant induced type I IFN production protects neonates from CHIKV 
infection. Mice (8 days of age) were injected i.p. with 25 µg of poly (I:C) and 24 hours later 
mice were infected s.c. in the right flank with CHIKV. (A) IFNα levels produced in the serum of 
neonatal mice 7 hours post injection with 25 µg poly (I:C). (B) Survival was monitored daily for 
four weeks and displayed as Kaplan-Meier survival curves. (C) Mice were scored for clinical 
signs of disease on days 7, 13 and 18 post-infection as discussed in materials and methods. (D) 
IFNAR1
-/- 
mice (8 days of age) were injected i.p. with 25 µg of pIC and 24 hours later mice were 
infected with CHIKV s.c. Survival was monitored daily.  
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Figure 2.5 
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Figure 2.6. ISG15, independent of UbE1L, plays a critical role during the neonatal 
response to CHIKV. (A-C) WT, UbE1L
-/- 
and ISG15
-/-
 mice were infected with 2x10
5
 PFU 
CHIKV s.c. at nine days of age. (A) Mice were monitored for lethality for 21 days with data 
displayed as Kaplan-Meier curves. (B) Skin and muscle homogenates from the site of infection 
were collected on day 2 post infection and analyzed for ISG15 expression by western blot. (C) 
Sera collected on days 1, 3 and 6 p.i. and analyzed as in (B).   (D and E) ISG15
-/-
, UbE1L
-/- 
and 
WT mice (8 days of age) were injected i.p. with (D) 25 µg or (E) 10 µg of pIC and 24 hours later 
mice were infected s.c. with 2x10
5
 PFU CHIKV. Survival was monitored daily for 21 days and 
displayed as Kaplan-Meier survival curves. Mice from all three genotypes that were pretreated 
with 25 µg of poly(I:C) and mock infected with PBS showed no lethality (data not shown).   
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Figure 2.6 
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Figure 2.7. ISG15
-/-
 and UbE1L
-/- 
mice display similar viral loads to WT mice. Nine day old 
WT, UbE1L
-/- 
and ISG15
-/-
 mice were injected with 2x10
5
 PFU CHIKV s.c. Tissue and sera were 
collected on days 1 (A) and 2 (B) post-infection and viral titers were determined by plaque assay; 
vertical bars represent standard error of the mean. A three way comparison of the three 
genotypes performed using a Kruskal-Wallis analysis was not significant except for the lung on 
day 2 post infection (*, where p < 0.05).   
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Figure 2.7 
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Figure 2.8. ISG15
-/-
 neonates display elevated cytokine levels during CHIKV infection. Nine 
day old WT, IFNAR1
-/-
, UbE1L
-/- 
and ISG15
-/-
 mice were injected with 2x10
5
 PFU CHIKV s.c. 
(A) The skin at the site of infection was harvested and the expression of IFNβ mRNA was 
evaluated by qRT-PCR. Vertical bars represent mean with standard error of the mean. (B and C) 
Serum was collected at the indicated time post-infection. (B) IFNα levels were quantified using 
an ELISA, vertical bars represent mean with standard error of the mean. Statistical comparison 
between the three genotypes via Mann-Whitney and Kruskal-Wallis test was not significant for 
both (A) and (B). (C) Cytokine and chemokine levels were measured by Bioplex assay (Mann-
Whitney * p < 0.05, ** p < 0.005). Vertical bars represent standard error of the mean.  
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Figure 2.8 
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Figure S2.1. Pre-treatment with IFNβ improves the outcome of CHIKV infection. Mice 8 
days of age were injected i.p. with 5000U of IFNβ and 24 hours later mice were infected s.c. in 
the right flank with 2x10
5 
PFU CHIKV. Mice were scored for clinical signs of disease on days 7, 
11 and 18 post-infection. The ability of the mice to return and land on its feet when flipped over 
was assessed. Paralysis was defined as the inability or delayed time to return (>5s). 3 
independent experiments are compiled. 
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Figure S2.1 
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Figure S2.2. Induction of ISG15 during neonatal CHIKV infection is largely dependent 
upon IFNAR1 signaling. Serum from nine day old WT, UbE1L
-/-
, ISG15
-/-
 and IFNAR
-/-
 mice 
infected s.c. with 2x10
5
 PFU CHIKV was collected on day 1 post-infection and ISG15 
expression was assessed by western blot.    
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Figure S2.2 
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Figure S2.3. The role of ISG15 during CHIKV infection is age dependent. WT, UbE1L
-/-
 and 
ISG15
-/-
 mice were infected with 2x10
5
 PFU CHIKV s.c. at either (A) eleven days of age, (B) 
twelve days of age, or (C) 6-8 weeks of age and were monitored for survival for 21 days post-
infection. Kaplan-Meier survival curves are shown.  
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Figure S2.3 
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Figure S2.4. Recombinant CHIKV viruses expressing WT ISG15 do not rescue ISG15
-/- 
mice. Recombinant CHIK viruses were generated to express the following proteins: wild type 
ISG15(-LRLRGG), non-conjugatable ISG15(-LRLRAA), and GFP(-GFP). (A) Schematic 
representation of recombinant CHIK clones adapted from Tsetsarkin, et al (2006). (B and C) 
BHK cells were infected with the indicated rCHIK viruses at an MOI=1. (B) Viral titers were 
measured at 0,6,12,24,48hrs p.i. by plaque assay. (C) Cell lysates were collected at 0,6,12, and 
24hrs p.i. and were analyzed for ISG15 expression by western blot. (D) Six day old ISG15
-/- 
mice 
were infected with either CHIK-GFP or CHIK-LRLRGG at 3x10
5
 PFU s.c. Mice were 
monitored for lethality for 21 days with data displayed as Kaplan-Meier curves.  
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Figure S2.4 
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Figure S2.5. CHIKV infected ISG15
-/- 
mice have increased ALT, AST, BUN serum levels 
and decreased serum glucose levels compared to WT and UbE1L
-/-
 mice. Nine day old WT, 
UbE1L
-/- 
and ISG15
-/- 
mice were infected with CHIKV (10
5
pfu s.c.). Serum was collected on day 
2 p.i. and sent to DCM for blood chemistry analysis. Analyte levels were compared to PBS mock 
treated WT and ISG15
-/- 
controls. * = p<0.05, ** = p<0.01 
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Figure S2.5 
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Table S2.1. Clinical signs in adult and infant cohort.  
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Table S2.2. Splenic lymphocyte subsets in naïve WT, UbE1L
-/- 
and ISG15
-/-
 neonatal mice 
(% total cell population, mean ± sem). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Type WT ISG15-/- UbE1L-/-
B cells (CD19+) 9.10 ± 3.0 5.27 ± 2.2 9.08 ± 0.0
NK cells (NK1.1+) 0.43 ± 0.0 0.35 ± 0.0 0.35 ± 0.0
CD4+ T cells (CD4+CD3+) 2.85 ± 0.6 2.15 ± 0.5 2.02 ± 0.1
CD8+ T cells (CD8+CD3+) 1.52 ± 0.3 1.11 ± 0.2 1.13 ± 0.0
Granulocytes (Gr1hi,F4/80low) 3.02 ± 0.3 2.58 ± 0.6 2.83 ± 0.0
Monocytes (Gr1int,F4/80int) 1.38 ± 0.0 1.38 ± 0.1 1.11 ± 0.0
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Abstract 
During Chikungunya virus (CHIKV) infection, ISG15 appears to play an immunoregulatory role 
that is independent of UbE1L mediated conjugation. To understand mechanistically how free 
ISG15 protects mice from infection, we characterized both intra- and extracellular unconjugated 
ISG15 using mass spectrometry. By purifying serum ISG15 from pIC stimulated mice, we have 
identified phosphorylation as a possible post translational modification of extracellular ISG15. 
We have also identified the previously uncharacterized 30kDa serum ISG15 band as ISG15 
conjugated to hemoglobin subunit beta-1. To identify non-covalent binding partners for 
intracellular ISG15, we pulled down cytosolic proteins from BMM using a tagged ISG15 
construct. Using this technique, we were able to identify over 140 unique potential binding 
partners for free ISG15. To verify the ability of ISG15 to bind to our mass spec hits, we have 
begun preliminary interaction studies and demonstrate that ISG15 co-ips with MDA5. As a start 
to functional studies, we also demonstrate that free ISG15 can regulate cytokine production in 
response to pIC stimulation.  Further characterization of both intra- and extracellular ISG15 will 
hopefully guide future experiments needed to determine ISG15s ability to regulate the host 
response to viral infection.  
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Introduction 
Since the initial discovery of ubiquitin as a mechanism to target misfolded proteins to the 
proteasome (1), this field has grown to include a multifaceted role for ubiquitin in a wide array of 
cellular pathways. Ubiquitin’s activity is not limited to K48-conjugated chains, but includes a 
variety of different linkages, activity for mono- and polyubiquitin, unanchored and conjugated 
chains (2-7). In addition to its conjugation ability, ubiquitin also mediates non-covalent 
interactions with proteins that contain Ubiquitin-binding domains(8, 9). We hypothesize that like 
ubiquitin, ISG15 plays a multi-functional role that is dependent on both covalent modifications 
and non-covalent interactions. How these interactions provide protection during viral infection is 
largely unknown. 
The mechanism by which ISG15 protects against viral infection is in-part dependent on 
the type of invading pathogen. Based on our viral models, we have come up with two potential 
non-mutually exclusive hypotheses on how ISG15 protects against virus infection. During 
influenza B and Sindbis virus infection (10-12), ISG15 regulates viral loads, suggesting that 
ISG15 can be directly antiviral. To date, this antiviral activity of ISG15 appears to be 
conjugation dependent. During Chikungunya (13), influenza A and Sendai virus infections (Dave 
Morales, unpublished), ISG15 does not regulate viral loads, suggesting an alternative mechanism 
for ISG15. We hypothesize that ISG15 can also regulate the host response to viral infection and 
dysregulation of the host response in ISG15
-/-
 mice can lead to lethality. The regulation of host 
response can either be conjugation dependent (influenza A and Sendai) or conjugation 
independent (Chikungunya virus). 
 Our Chikungunya virus model provided a unique opportunity to go after a conjugation 
independent mechanism for ISG15. Upon further investigation, we have also identified other 
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alphaviruses where the role of ISG15 appears to be UbE1L independent, including neonatal Ross 
River Virus and Barmah Forest Virus infections (Fig. S3.1). Based on our CHIKV model, we 
hypothesized that ISG15 regulates the immune response to viral infection, as we observed 
increased pro-inflammatory cytokine production in ISG15
-/- 
despite similar viral loads as WT and 
UbE1L
-/-
 mice (13). Free ISG15 is found both intra- and extracellularly, therefore we have two 
primary models by which free ISG15 could impact an immune response: (1) Extracellular free 
ISG15 binds to an unidentified cell surface receptor which then modulates downstream cellular 
signaling and/or (2) Intracellular free ISG15 binds non-covalently to intracellular molecules, 
which then leads to altered cell signaling pathways. The key to addressing both of these potential 
mechanisms is to identify the non-covalent binding partners for free ISG15.  
 Free ISG15 has been suggested to have cytokine like activity. Non-conjugated ISG15 can 
be detected in the sera of humans treated with IFNβ as well as mice infected with certain viruses 
(14). Recombinant ISG15 has been shown to increase NK cell proliferation and lytic activity 
(15). Extracellular ISG15 has also been shown to act as a neutrophil chemoattractant and can 
upregulate e-cadherin expression on dendritic cells (16, 17). Recently, recombinant ISG15 in 
concert with IL-12 stimulation has been shown to upregulate IFNγ (18). The cytokine activity of 
ISG15 may be biologically significant, as humans with null mutations for ISG15 display 
Mendelian susceptibility to mycobacterial disease (MSMD), possibly due to lack of ISG15 
mediated IFNγ production (18). Although ISG15 appears to have cytokine activity, a receptor for 
ISG15 has not been identified. 
Much less is known about the role of free ISG15 within a cell. During in vivo viral 
infection, both free ISG15 and ISG15 conjugates can be detected in tissue homogenates (13, 19).  
The over-expression of ISG15 has also been shown to disrupt Nedd4 ligase activity and inhibit 
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Ebola virus VLP release, although it is unclear whether or not this activity is conjugation 
dependent (20-22) . Recent research within the ubiquitin field has described a role for 
unanchored polyubiquitin chains, shown to regulate TAK1 activation as well as RIG-I and 
MDA5 signaling (23-25). Unanchored polyubiquitin chains generated by TRAF6 (23) or TRIM5 
(26) bind to and activate the TAK1 complex, which influences downstream NF-κB signaling. 
Unanchored polyubiquitin chains also bind to the CARD domains of RIG-I and MDA5, which 
allows for oligomerization and optimal IRF3 activation (24, 25). Binding partners for free ISG15 
within a cell is largely unknown. 
The following describes our initial steps towards identifying mechanisms for both intra 
and extracellular ISG15. Through mass spectrometry, we have identified phosphorylation as a 
possible post-translational modification for serum ISG15. We have also identified the 30kDa 
ISG15 band normally found in the serum of infected mice as ISG15 bound to hemoglobin 
subunit beta-1. By generating recombinant tagged ISG15, we have identified over 140 potential 
binding partners for intracellular ISG15 via mass spectrometry. Preliminary experiments have 
been used to verify ISG15s ability to interact with the proteins identified from our mass spec 
analysis and we demonstrate that ISG15 can co-immunoprecipitate with MDA5. Finally, we 
demonstrate that free ISG15 can regulate cytokine production in response to pIC stimulation. 
Our mass spec analysis of both extra- and intracellular ISG15 will aid future studies in 
identifying a mechanism of action for free ISG15. 
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Results 
 
Serum ISG15 may be phosphorylated and the 30kDa ISG15 band is ISG15 conjugated to 
hemoglobin subunit β-1. 
Although ISG15 has been suggested to have cytokine like activity (15-17), a receptor for 
ISG15 has not been identified. To complement ongoing studies for the ISG15 receptor, we 
decided to characterize the natural secreted form of ISG15 to identify any post translational 
modifications that may or may not be required for its binding/activity. In addition, we also hoped 
to identify the previously unknown 30kDa ISG15 conjugate that is found in the serum of virally 
infected WT mice (13).  
To identify post translational modifications as well as the 30kDa ISG15 conjugate, we 
purified serum ISG15 and sent isolated bands to the Yale MS & Proteomics facility. Adult WT 
and ISG15
-/-
 mice were injected with 50ug pIC ip, which is sufficient to induce serum ISG15 
expression (data not shown). Serum was harvested on day 2 post treatment and ISG15 was 
immunoprecipitated. Pulldown of ISG15 was confirmed by western blot analysis and bound 
proteins were identified by SyproRuby stain (Fig. 3.1). Comparison of WT and ISG15
-/-
 serum 
allowed for identification of unique bands found only in WT serum, which were excised and sent 
for mass spec analysis.  
Gel bands were digested with trypsin and then analyzed via LC-MS/MS. 
Phosphopeptides were enriched by passage over a titanium dioxide (TiO2) column.  Results were 
analyzed using the Swissprotein database and the confidence level was set to 95%. Two lower 
molecular weight bands around 15kDa described as ISG15 lo and ISG15 hi were identified as 
hemoglobin (alpha (15.1kDa) and beta-1 (15.8kDa) subunits) and ISG15, respectively. Two 
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phosphorylated peptides were identified from the ISG15 band: a threonine at position 24 (N-
terminal domain) and a tyrosine at position 139 (C-terminal domain) (Fig. 3.2 A and B) No other 
modifications were found, with searches for methylation, acetylation, ubiquitination and 
sumolyation. Phosphorylation of ISG15, either intra- or extracellular, has not been described and 
will need to be verified.  
Four higher molecular weight bands (between 30-40kDa) were sent for basic protein 
identification, two from WT serum (W1 and W2) and the corresponding negative control bands 
from ISG15
-/-
 serum (S1 and S2).The 30kDa ISG15 conjugate (W2) was identified as ISG15 
(MW=17.8kDa, 42% coverage) and hemoglobin subunit beta-1 (MW=15.8kDa, 59% coverage). 
Neither of these proteins were identified in the corresponding ISG15
-/- 
band S2. Numerous 
unique proteins were identified for the W1 band, which based on our western blot analysis did 
not appear to be an ISG15 conjugate. Based on the function of the identified proteins, we 
hypothesized that the most likely candidate is the hemoglobin binding protein haptoglobin 
(MW=38.7kDa, 5.5% coverage).  
In an attempt to confirm that the ISG15 30kDa band is ISG15 conjugated to hemoglobin 
subunit beta-1, we ran a western on CHIKV infected serum samples as well as our serum ISG15 
pulldown and stained with an anti-hemoglobin antibody (Fig. 3.3). From our ISG15 pulldown, 
we were able to detect the 30kDa band with the hemoglobin antibody. No 30kDa band was 
detected in CHIKV infected serum, although we observed robust staining for free hemoglobin. 
We hypothesize that only a small fraction of serum hemoglobin is modified, resulting in our 
inability to detect the 30kDa band with the hemoglobin antibody in straight serum. A functional 
role for the 30kDa serum ISG15 conjugate has not been described. 
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Identification of Intracellular Binding Partners for Free ISG15 using Mass Spectrometry. 
We hypothesized that free intracellular ISG15 could have activity within a cell, 
independent of its ability to conjugate to target proteins, by binding non-covalently to other 
intracellular proteins. Therefore, we generated recombinant ISG15 for immunoprecipitation 
studies to identify potential binding partners by mass spectrometry. 
ISG15 was cloned into a pfuse-hIgG1e3 Fc2 expression vector that includes a secretion 
signal and a C-terminal mutant human Fc tag that is unable to bind to FcR. DIII (from WNV) 
was also cloned to act as a negative control. Recombinant protein expression was confirmed by 
western blot analysis (Fig. 3.4A). BMM, which produce many of the cytokines that were 
elevated in our CHIKV model, were chosen as the target cell. Cytosol from IFN and pIC 
stimulated ISG15
-/-
 BMM was mixed with the recombinant protein and ISG15-Fc was 
immunoprecipitated. Unique bands were identified by comparing ISG15-Fc and DIII-Fc 
pulldowns and excised for basic protein identification by mass spec (Danforth facility) (Fig. 
3.4B). Similar to our serum ISG15 pulldown, gel bands were trypsinized and analyzed using LC-
MS/MS. Data was searched against the NCBInr database.  
Over 140 proteins were identified by mass spec analysis (after subtracting available 
negative control hits) (Table 3.1). Proteins identified represent a variety of cellular pathways, 
including innate immunity, vesicle sorting, cytoskeletal, ribosomal components and heat shock 
proteins. Priority for studying potential hits was given by the following criteria: (1) interest (i.e. 
innate immunity), (2) proteins that were also identified in Nadia’s Y2H screen (PCBP1 and 
Clathrin, unpublished), (3) protein size matched the isolated protein band and (4) protein is not 
found in the negative control band. Based on these criteria, the following proteins were identified 
for initial follow up studies: MDA5, p62 (sequestosome-1), p40phox (NCF4), STAT1/2, and 
104 
 
poly(C) binding protein 1 (PCBP1). Additional proteins found in Table 3.1 may share equal 
potential for (1) binding to ISG15 and (2) important biological activity.  
 
Human ISG15 co-precipitates with human MDA5 
One of the proteins identified in our mass spec analysis was MDA5, a known 
intracellular viral RNA sensor. MDA5, in combination with other viral sensors, has been shown 
to play a role during CHIKV infection (27). Unanchored polyubiquitin chains have also been 
shown to regulate MDA5 function (25).  Therefore, we thought that MDA5 was a good 
candidate for an ISG15 binding partner. 
To confirm MDA5 as a binding partner for free ISG15, we over-expressed flag tagged 
human MDA5 with either vector alone or with human or mouse ISG15 (without the conjugation 
system) by transfecting 293T cells. Flag-MDA5 was immunoprecipitated and western blot 
analysis was used to verify the pulldown (Flag) and check for the presence of free ISG15 
(ISG15). Human ISG15 can be pulled down by anti-Flag human MDA5 immunoprecipitation 
(Lane 2- Fig. 3.5). Interestingly, mouse ISG15 did not co-ip with human MDA5 (Lane 3), which 
may suggest a species specific interaction. We also attempted pulldowns with two truncated 
forms of human MDA5 that were obtained from Michael Gale’s lab: MDA5 1-294 (CARD 
domains) and MDA5 295-1025 (RNA helicase domain) (Lanes 4-7)(28). Human ISG15 could be 
pulled down by both of these constructs (Lanes 5 & 7), although there appeared to be more 
ISG15 with MDA5 1-294. We also attempted to pulldown ISG15 with Flag human RIG-I, which 
was not identified in our mass spec analysis. We saw only a weak band for human ISG15, 
suggesting weak or no binding, and no bands for mouse ISG15 (Lanes 8-9). Therefore, human 
ISG15 co-precipitates with human MDA5 but not RIG-I. Preliminary data also suggests that 
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ISG15 may co-ip with additional binding partners identified via mass spec, including STAT1, 
p62 and p40phox (NCF4). 
 
ISG15
-/-
 mice and cells have increased IL-6 production in response to pIC stimulation. 
If we are able to confirm MDA5 as a binding partner for free ISG15, it will be important 
to determine if there is a functional consequence for this interaction. The best approach will be to 
stimulate MDA5 in the presence or absence of ISG15. MDA5 has been shown to be responsible 
for cytokine production (IFNα, TNFα, MCP-1, IL-6) in response to naked pIC and complexed 
pIC (transfection) (29). Cytokine production following pIC stimulation is primarily MDA5 
dependent, althoughTLR3 can also produce these cytokines in response to pIC (29). We 
hypothesized that ISG15 regulates cytokine production downstream of MDA5 signaling. 
Therefore, we investigated the ability of ISG15 to regulate cytokine production in response to 
pIC.   
In order to address whether ISG15 could directly affect cytokine production, we 
developed an in vitro model to examine ISG15s impact on pIC stimulation. Primary cells (BMM, 
BMDC, and muscle fibroblasts) were generated from WT, UbE1L
-/-
 and ISG15
-/-
 mice. Cells 
were pretreated with IFNβ to induce ISG15 (data not shown). 24hrs post IFNβ treatment, cells 
were then stimulated with pIC (10ug/mL). Cell supernatants were harvested at 4,12 and 24hrs 
post pIC stimulation. Cytokine production (TNFα, IL-1β, IL-6, IL-10, and various chemokines) 
were assessed by bioplex.  
Production of IL-6 following pIC stimulation appeared to replicate our in vivo CHIKV 
results: WT and UBE1L
-/-
 cells produce similar levels of IL-6, whereas ISG15
-/-
 cells have 
increased IL-6 production (at best 2-fold) at 12 and 24hrs post stimulation. This phenotype was 
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found for BMM (Fig. 3.6A) and primary muscle fibroblasts (Fig. 3.6B). Preliminary data 
suggests that this same trend was also observed in BMDC, although IL-6 production was much 
lower than BMM and muscle cells (data not shown). Therefore, under these conditions, free 
ISG15 appears to act as a negative regulator of IL-6 production following pIC stimulation. 
To complement our in vitro findings, we also developed an in vivo model for pIC 
stimulation. Nine day old WT, UbE1L
-/-
, and ISG15
-/-
 mice were injected with pIC (10ug) s.c. 
and serum was harvested at 6 and 24hrs post treatment. ISG15 could be found in the serum of 
pIC stimulated WT and UbE1L
-/-
 mice at both 6 and 24hrs post stimulation (data not shown). 
Similar to our in vitro findings, ISG15
-/-
 mice display elevated levels of IL-6 production at 6hrs 
post treatment compared to WT and UbE1L
-/-
 mice (Fig. 3.6C). This data suggests that free 
ISG15 regulates IL-6 production following pIC stimulation. 
Similar to IL-6, production of IL-10 following pIC stimulation in BMM appeared to 
replicate our in vivo CHIKV phenotype (Table 3.2). ISG15
-/-
 BMM pretreated with pIC 
produced more IL-10 (at best 2-fold) than WT and UbE1L
-/-
 BMM 12 and 24hrs post 
stimulation. As IL-6 is a known regulator of IL-10 (30), it is unclear as to whether this phenotype 
is due to ISG15s ability to directly regulate the IL-10 pathway or simply due to increased levels 
of IL-6. BMDCs and primary muscle fibroblasts did not produce IL-10 in response to pIC 
stimulation, suggesting that unlike IL-6, this phenotype is cell type dependent. 
The other analytes that we evaluated did not show the same trend as IL-6 and IL-10 
production (Table 3.2). WT BMM display increased TNFα production compared to UbE1L-/- and 
ISG15
-/-
 BMM 4hrs after pIC stimulation. In addition, IL-1β production was not detected and no 
difference was observed for chemokine levels (MIP-1α, MCP-1 and GM-CSF). In addition, 
ISG15 mediated regulation appears to be cell type dependent, as different cells produced 
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different cytokine patterns in response to pIC stimulation. Interestingly, changing the type of 
TLR stimulation, including LPS (TLR4) or Imiquimod+ATP (inflammasome activation) also 
produced a different pattern of ISG15 mediated cytokine regulation (Figure S3.2 and Table 3.2). 
Preliminary data suggests that IL-6 production following LPS stimulation in vitro (Fig. S3.2A) 
or in vivo (Fig. S3.2B) is positively regulated by ISG15 conjugation. Following inflammasome 
activation, production of IL-1β appears to be negatively regulated by ISG15 conjugation (Table 
3.2)Therefore, free ISG15 does not act as a master regulator for cytokine production and 
regulation may be dependent on select cytokine signaling pathways, the type of cell as well as 
the type of stimulation. 
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Discussion 
Free extracellular ISG15 has been described to have cytokine activity, although how 
ISG15 mediates this activity is unknown (15-17). Even less has been reported for the activity of 
free intracellular ISG15 (20-22). However, our CHIKV model, as well as recent reports that 
confirm earlier cytokine studies (18), suggest that free ISG15 has an important role in the 
immune response to both viral and bacterial pathogens. To setup future mechanistic studies, we 
have characterized both free forms of ISG15, intra- and extracellular, using mass spectrometry. 
Our results show that serum ISG15 may be modified by phosphorylation, which may or may not 
be necessary for ISG15 function. In addition, we identify the 30kDa ISG15 conjugate commonly 
found in virally infected WT mice as ISG15 conjugated to hemoglobin subunit beta-1. For 
intracellular ISG15, we have identified 146 potential binding partners that are involved in 
multiple cellular pathways. Preliminary co-ip data confirms that at least some of these hits may 
be valid, as ISG15 can co-ip with MDA5. We also demonstrate that ISG15 can regulate cytokine 
production in response to pIC stimulation, although it is unclear if this is dependent on ISG15s 
interaction with MDA5.  
 Recombinant ISG15 has been shown to regulate innate immune cell responses, affecting 
the activity of monocytes, neutrophils and NK cells. To fully understand how extracellular 
ISG15 mediates its activity, a receptor for serum ISG15 must be identified. As a requisite step in 
identifying an ISG15 receptor, we have identified phosphorylation as a potential post-
translational modification of 15kDa serum ISG15 (Fig. 3.1 and 3.2). Interestingly, we identified 
two phosphopeptides for ISG15, each corresponding to one of the two ubiquitin domains of 
ISG15: Thr
24
 N-terminus and Y
139
 C-terminus. Mutagenesis of these two sites will help confirm 
whether ISG15 is phosphorylated and may aid in future functional studies. The consequences of 
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ISG15 phosphorylation are unknown. It is unclear if phosphorylation affects the secretion or 
activity of ISG15, if intracellular ISG15 is also modified, and what percentage of total ISG15 
gets modified. Generation of recombinant ISG15 in the literature was not described as being 
phosphorylated and yet activity was still reported, so it is unclear if phosphorylation will affect 
the activity of secreted ISG15.  
We have also identified the 30kDa serum ISG15 conjugate as ISG15 bound to 
hemoglobin subunit beta-1 (Fig. 3.1 and 3.3). To our knowledge, the role of the 30kDa conjugate 
has not been investigated and its function is unknown. Its role outside of the cell may have an 
important biological function or it may be a byproduct of red blood cell lysis. Intracellular 
ISGylated hemoglobin may also have an important function that remains to be investigated. 
Although hemoglobin expression is predominantly found in red blood cells, it can also be 
expressed in additional cell types, including alveolar cell lines, activated macrophages from adult 
mice and embryonic neurons (31-33). We hypothesize that identification of hemoglobin as the 
ISG15 lo band may result from degradation of the 30kDa ISG15 band or may result from non-
covalent association with the ISG15 or hemoglobin portion of the 30kDa band. Indeed, it is 
known that hemoglobin beta and alpha subunits form a tetramer complex. We suspect that the 
unique higher molecular weight band W1 is likely haptoglobin. Haptoglobin, which binds to and 
sequesters serum hemoglobin, may be coming down in our ISG15 ip due to its interaction with 
the hemoglobin subunit beta (34). However, this also remains to be verified. Identification of the 
ISGylated hemoglobin subunit beta-1 residue (via mass spec (diglycine shift) or Lysine 
mutagenesis) may aid in the discovery of a functional role for the 30kDa ISG15 conjugate.  
 Most importantly, we have shown that free ISG15 has the capacity to bind to many 
different intracellular proteins, independent of its conjugation activity (Fig. 3.4). Most of these 
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potential binding targets remain to be verified and may be either direct or indirect ISG15 binding 
partners. We recognize that ISG15 may be binding to only a select few of these potential targets 
and a large number of hits that we have generated may result from the formation of protein 
complexes that are not dependent on direct ISG15 binding. Nonetheless, these mass spectrometry 
hits will allow us to focus on different cellular pathways that free ISG15 may be involved in, 
including innate immune signaling and vesicle sorting pathways. Our mass spec hits are specific 
for IFN/pIC stimulated BMM, therefore may not represent additional binding partners in 
different cells or in response to other forms of stimulation (TLR4, inflammasome, etc). 
 The results that we have generated from our non-covalent pulldown have directed our 
attention to cellular pathways that ISG15 may be involved in. We note that ISG15 associates 
with several ribosomal components and proteins associated with protein translation. We 
hypothesize that this association may be linked to the conjugation activity of Herc5, the main E3 
ligase for ISG15 that also associates with ribosomal subunits (35). Several proteins involved in 
vesicular transport were also identified, including the retrograde transport proteins SNX1 and 
SNX2. As ISG15 lacks a signal peptide necessary for classical protein secretion, we hypothesize 
that ISG15s ability to interact with vesicular proteins may lead to discovery of the secretion 
mechanism for ISG15. Alternatively, ISG15s ability to interact with the vesicular transport 
pathway may be a way to regulate cell responsiveness by retrograde transport of cell surface 
receptors (36) or may reflect previously reported data where ISG15 impacts VLP release via the 
ESCRT pathway (22). Perhaps unexpectedly, we also identified several proteasome regulatory 
subunits, as a role for ISG15 in proteasome mediated degradation has not been described. Lastly, 
as ISG15 plays a vital role during viral infection, we hypothesize that the proteins that we have 
identified as innate immune proteins may represent important binding interactions for ISG15. 
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Indeed, we have identified the PRRs MDA5, LGP2, and DAI as well as additional proteins 
known to play a role in cytokine production, such as FLN29 and BCAP1 (37, 38). In Chapter 4, 
we briefly discuss the importance of some of the proteins that we have identified for use in future 
functional studies. 
 In an attempt to verify targets of our intracellular ISG15 analysis, we demonstrate that 
ISG15 co-ips with MDA5 (Fig. 3.5). The ability of ISG15 to directly bind MDA5 has not been 
demonstrated and will require further study. MDA5 is an exciting potential target for ISG15 as it 
is a known sensor for CHIKV, plays a role in cytokine production, and is also known to be 
regulated by unanchored ubiquitin chains (25, 27, 39). Unanchored polyubiquitin chains bind to 
the Card domains of both MDA5 and RIG-I, which allows for oligomerization and full activation 
of downstream signaling (25). One hypothesis that could explain our observations is that free 
ISG15 disrupts the binding of unanchored ubiquitin chains to MDA5, resulting in down-
regulation of this signaling pathway. Therefore, when ISG15 is absent, the MDA5 signaling 
pathway will remain active, resulting in increased cytokine production observed in ISG15
-/-
. 
Interestingly, RIG-I was not identified in our mass spec analysis and ISG15 did not co-ip with 
RIG-I in our overexpression studies, suggesting that ISG15s ability to co-ip with MDA5 may 
result from a specific interaction.  
 In an attempt to show that there is a functional consequence for ISG15s interaction with 
MDA5, we also stimulated cells and mice with the MDA5/TLR3 agonist pIC (29). We were 
encouraged to find that IL-6 production following pIC stimulation in vitro and in vivo gave 
similar results to our CHIKV model (Fig. 3.6). Preliminary data generated by infecting primary 
muscle fibroblasts with CHIKV suggested that IL-6 production did mirror our in vivo findings, 
although the levels of IL-6 produced were significantly lower than following pIC stimulation 
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(data not shown). We hypothesize that this may be due to CHIKVs ability to interfere with 
transcription and translation (40). Although we were able to demonstrate a role for ISG15 in 
cytokine production, we were unable to generate an in vitro model that completely replicates our 
in vivo CHIKV phenotype. This may be due to our inability to generate the complex cellular and 
tissue interactions found in vivo or due to using pIC stimulation instead of CHIKV infection. 
We hypothesize that ISG15 may regulate MDA5 mediated signaling, however, we cannot 
rule out a contribution of TLR3 in our pIC stimulation studies. We also cannot explain why only 
some and not all cytokines appear to be regulated by free ISG15. If our hypothesis that ISG15 
can directly regulate PRR signaling was correct, we would hypothesize that more cytokines 
would be dependent on free ISG15 (which we observe from our in vivo model but not in vitro). 
An alternative hypothesis may be that ISG15 regulates PRR cytokine production farther 
downstream of the initial PRR signaling pathway, which could allow for individual cytokine 
regulation.    
 In summary, we have begun preliminary functional studies to identify a mechanism of 
action for free ISG15. We have characterized the natural secreted forms of ISG15, identifying 
phosphorylation as a potential post translational modification and identifying the 30kDa 
conjugate as ISG15 bound to hemoglobin subunit beta-1. We have also identified many different 
potential binding partners for free intracellular ISG15 and have verified ISG15s ability to co-ip 
with MDA5. We demonstrate that ISG15 regulates cytokine production following PRR 
activation and show that ISG15
-/-
 have elevated IL-6 levels following pIC stimulation.  Free 
ISG15s ability to form non-covalent interactions with other proteins represents an exciting 
opportunity to identify a conjugation independent mechanism for ISG15.    
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Materials and Methods 
 
Mice 
 Mouse studies were performed at Washington University in St. Louis in accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health and following the International Guiding Principles for Biomedical Research 
Involving Animals.  The protocols were approved by the Animal Studies Committee at 
Washington University (#20090287). The generation of both the ISG15
-/-
 and UbE1L
-/-
 mice has 
been previously described (41, 42). Congenic SNP analysis (Taconic laboratories) of UbE1L
-/-
 
and ISG15
-/-
 mice confirmed that these mice were fully backcrossed, with 99.93% and 99.72% 
identity to C57BL/6 mice, respectively. For serum ISG15, adult 6-8week old WT and ISG15
-/-
 
mice were injected with 50ug pIC i.p. and serum was harvested 48hrs post-treatment. For in vivo 
pIC stimulation, 9 day old WT, UbE1L
-/-
 and ISG15
-/-
 pups were injected with 10ug pIC s.c. 
 
Purification of Serum ISG15 
 Serum from pIC treated WT and ISG15
-/-
 adult mice was incubated with monoclonal 3C2 
anti ISG15 coupled beads, washed with PBS and eluted using a glycine buffer (0.1M, pH 2.5). 
Pulldown of ISG15 was confirmed using western blot analysis by running proteins on a 12% Tris 
gel, transferring to a polyvinylidene fluoride membrane, and blotting with a rabbit anti-ISG15 
polyclonal serum (1:5000) as previously described (19). Bound proteins were run on a precast 
12% Tris gel and identified using SyproRuby stain. Unique bands were excised and sent for 
identification of post-translational modifications and basic protein identification by mass 
spectrometry.      
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Generation of tagged ISG15 for Non-covalent pulldowns 
Mouse ISG15 and the WNV domain DIII were cloned into the expression vector pfuse-
hIgG1e3 Fc2 (invivogen), which includes a signal peptide for secretion and a C-terminal Fc tag. 
Generation of Fc tagged constructs was confirmed by transfecting 293T cells using 
Lipofectamine and harvesting supernatant and cell lysate 48hrs post transfection. Proteins were 
run on a 12% Tris gel and transferred to a polyvinylidene fluoride membrane for western blot 
analysis. Anti-human Fc (Goat anti-human Fc-HRP: Jackson Immunoresearch 109-035-098) was 
used for detection. The membrane was incubated in 5-10% milk 1:15000 antibody dilution for 1-
2hrs,washed 4x with PBS-Tween and resolved with Chemiluminescent HRP substrate (Millipore 
Immobilon Western: WBKLS0500). 
Mass production of Fc-tagged proteins was performed by transfecting 293 suspension 
cells (293F cells) provided by Dr. Daved Fremont. Cells were grown in serum free media (Gibco 
FreeStyle 293 media; cat no: 12338-018) at 37C, 8% CO2 in a ThermoScientific 500mL flask 
(4115-0500 PETG flask with vented closure). Cells were seeded at 0.5x10
6
 cells/mL in 100mL 
the day before transfection of the Fc constructs using PEI (1ug DNA/mL). Supernatant was 
harvested every three days. Fc constructs were purified from supernatant using Protein A beads 
and dialyzed against PBS using Slide-A-Lyzer Dialysis Cassettes (ThermoScientific). 
Purification was confirmed using western blot analysis described above and SyproRuby staining.  
 For identification of binding partners, purified Fc constructs was mixed with cytosol from 
bone marrow macrophages (BMM). Generation of BMM is previously described. ISG15
-/-
 BMM 
were lysed with digitonin buffer and the cytosol enriched fraction was incubated with the Fc 
constructs overnight. Fc proteins along with binding partners were purified using Protein A 
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beads. Bound proteins were run on a precast 12% Tris gel and identified using SyproRuby stain. 
Unique bands were excised and sent for protein identification by mass spectrometry.      
 
Mass Spectrometry 
 Unique bands for the serum ISG15 pulldown were sent to the MS & Proteomics WM 
Keck Foundation Biotechnology Resource Laboratory at Yale University. Analysis was led by 
Dr. Kathryn Stone and Jean Kanyo. Gel bands were digested with trypsin and then peptides were 
separated on a Waters nanoACQUITY (75 µm x 250 mm eluted at 300nl/min.) with MS analysis 
on a LTQ Orbitrap mass spectrometer. ISG15 lo and hi gel bands were also passed over a 
titanium dioxide column to enrich for phosphopeptides. The LC-MS/MS results were searched 
using the SwissProt database. Mascot distiller and the Mascot search algorithm were used for 
database searches. Unique bands for the Fc-ISG15 pulldown were sent to the Donald Danforth 
Plant Science Center Proteomics and Mass Spectrometry Facility in St. Louis with analysis by 
Dr. Sophie Alvarez. As described above, gel bands were digested with trypsin for LC-MS/MS 
analysis. Confidence level for all hits was set at 95%. 
     
Co-immunoprecipitations 
 293T cells were transfected (Lipofectamine) with human or mouse ISG15 alone or in 
combination with Flag tagged target constructs. Human MDA5 and RIG-I constructs were 
obtained from Dr. Michael Gale’s lab and are previously described (28). 24hrs post transfection, 
cells were lysed with digitonin and cell lysate was incubated with anti-Flag beads. Pulldown of 
Flag and/or ISG15 constructs was confirmed via western blot analysis, as described above. Anti-
Flag and rabbit anti-ISG15 polyclonal sera was used for protein detection.  
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TLR Stimulation and Cytokine Analysis 
For in vitro stimulation, primary bone marrow derived macrophages, bone marrow 
derived dendritic cells and primary muscle fibroblasts were generated. Cells were pretreated with 
10U/mL IFNβ. 24hrs post IFN treatment, cells were stimulated with pIC (10ug/mL), LPS 
(10ng/mL) or imiquimod pulsed with ATP (43). Cell supernatants were harvested at 4, 12, and 
24hrs post treatment. For in vivo stimulation, 9 day old mice were treated with pIC (10ug) s.c. 
and serum was harvested 6 and 24hrs post stimulation. Cytokines were measured using Luminex 
technology with a customized 6plex from Biorad. 
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Figure 3.1. Mass spectrometry analysis of serum ISG15 indicates that free ISG15 (ISG15 
Hi) may be phosphorylated and the 30kDa band (W2) is ISG15 conjugated to hemoglobin 
subunit beta-1. WT and ISG15
-/- 
adult mice were injected with 50ug pIC i.p. and serum was 
harvested on day 2 post treatment. Serum ISG15 was pulled down with aISG15 coupled beads 
(mouse monoclonal). (A) Western blot was used to confirm pulldown of ISG15 (rabbit 
polyclonal). (B) ISG15 and associated bands were identified by Syproruby stain. Bands sent off 
for mass spec (Yale) are highlighted in red.   
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Figure 3.1 
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Figure 3.2. Thr
24
 and Tyr
139
 were identified as potential phosphorylation sites for serum 
ISG15. WT and ISG15
-/- 
adult mice were injected with 50ug pIC i.p. and serum was harvested 
on day 2 post treatment. Serum ISG15 was pulled down with aISG15 coupled beads (mouse 
monoclonal). Purified protein was digested with trypsin and phosphopeptides were enriched 
using a TiO2 column for mass spec analysis at the Yale MS & Proteomics facility. 
Phosphorylated residues (red) from their respective peptides (black) are represented in the 
context of the mouse ISG15 amino acid sequence (processed)(grey).  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MAWDLKVKMLGGNDFLVSVTNSMTVSELKKQIAQ
KIGVPAFQQRLAHQTAVLQDGLTLSSLGLGPSSTVM
LVVQNCSEPLSILVRNERGHSNIYEVFLTQTVDTLKK
KVSQREQVHEDQFWLSFEGRPMEDKELLGEYGL
KPQCTVIKHLRLRGG
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Figure 3.3. The 30kDa ISG15 band appears to be ISG15 conjugated to hemoglobin subunit 
beta-1 (preliminary data). (A) Serum ISG15 from pIC stimulated adult mice was pulled down 
with aISG15 coupled beads and blotted for aISG15 and αHemoglobin β (αHgbβ) (B) Nine day 
old WT, UbE1L
-/- 
and ISG15
-/- 
neonates were infected with CHIKV (10
5
pfu s.c.). Serum was 
harvested on day 2 post infection and blotted for aISG15 and αHgbβ.  
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Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT   ISG15-/- WT   ISG15-/-
kDa
ISG15 Hgb
25
15
25
25
15
15
WT             UbE1L-/- ISG15-/-
ISG15
Hgb
A B
123 
 
Figure 3.4. Generation of recombinant ISG15-Fc and identification of non-covalent binding 
partners. ISG15 and DIII (WNV) were cloned into an expression vector that includes a 
secretion signal and a C-terminal mutated human Fc tag that is unable to bind to FcR. 293S cells 
were transfected and Fc tagged proteins were purified from supernatant with Protein A beads. 
Bound Fc proteins were eluted with glycine, collected in Tris and dialyzed in PBS. (A) Anti-Fc 
western blot was used to confirm the presence of both proteins after the purification process. The 
lower MW band in the ISG15-Fc fraction appears to be a cleaved Fc contaminant. (B) Purified 
proteins were then mixed with cytosol from IFNβ/pIC stimulated ISG15-/- BMM. ISG15-Fc was 
pulled down with Protein A beads along with bound proteins. Unique bands were sent for mass 
spec protein id (Danforth). Excised bands are indicated on the right insert (ISG15-Fc bands in 
blue, control bands in green).   
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Figure 3.4 
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Figure 3.5. Human ISG15 interacts with human MDA5 by co-ip. Flag tagged hMDA5 (or 
hRIG-I) was coexpressed with untagged hISG15 (1:1 ratio) in 293T cells. Cells were lysed with 
Digitonin and Flag proteins were immunoprecipitated. Western blot was used to confirm protein 
expression in bound (A) and unbound (B) fractions.  
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Figure 3.5 
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 Figure 3.6. ISG15
-/- 
cells and mice produce more IL-6 than both WT and UbE1L
-/- 
following pIC stimulation. Bone marrow macrophages (BMM) (A) and primary muscle 
fibroblasts (B) were pretreated with IFNb for 24hrs and then stimulated with pIC (10ug/mL). (C) 
WT, UbE1L
-/- 
and ISG15
-/- 
mice were injected with 10ug pIC s.c. (A-C) Supernatant and serum 
was harvested at the indicated timepoints and IL-6 levels were measured by bioplex.   
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Figure 3.6 
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Figure S3.1. ISG15, independent of UbE1L, plays a critical role during the neonatal 
response to certain alphavirus infections. WT, UbE1L
-/- 
and ISG15
-/-
mice were infected with 
(A) 10
3
pfu RRV s.c. at 14 days of age, (B) 10
5
pfu VEEV TC-83 s.c. at 9 days of age, (C) 10
6
pfu 
Barmah Forest Virus  s.c. at 9 days of age, (D) 10
5
pfu Bebaru s.c. at 9 days of age. Mice were 
monitored for lethality for 21 days with data displayed as Kaplan-Meier curves. Similar survival 
for Bebaru was observed at 100pfu. No lethality was observed in adult ISG15
-/- 
mice infected 
with TC-83 (10
4
pfu i.c.) or Bebaru (10
6
pfu s.c.).  
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Figure S3.1 
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Figure S3.2. ISG15
-/- 
and UbE1L
-/- 
mice and cells produce less IL-6 in response to LPS 
compared to WT mice/cells (preliminary data). (A) WT, UbE1L
-/- 
and ISG15
-/-
 BMM were 
pretreated with 10U IFNb 24hrs before stimulation with LPS. Supernatants were collected at 4 
and 12hrs post LPS treatment. IL-6 levels were measured by bioplex. (B) Nine day old WT and 
ISG15
-/-
 mice were treated with LPS i.p. and serum was harvested 6 and 24hrs post treatment. 
IL-6 levels were measured by bioplex.  
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Figure S3.2 
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Table 3.1 Potential Non-Covalent Binding partners for free ISG15 identified via mass spec 
(ISG15-Fc pulldown with IFN/pIC stimulated ISG15-/- BMM).  
 
Biological Process NCBI Accession 
Number 
Gene Name Protein Name #U 
pep 
Signaling  13959396 Iqgap1 Ras GTPase-activating-like protein IQGAP1 15 
 148668602 Ap3bp1 AP-3 complex subunit beta-1 6 
 114326482 Stat1 Signal transducer and activator of 
transcription 1 
7 
 13633965 Stat2 Signal transducer and activator of 
transcription 2 
8 
 187471159 Hmha1 Minor histocompatibility protein HA-1 6 
 170172575 Inppl1 Phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase 2 
7 
 148701340 Fermt3 Fermitin family homolog 3 7 
 168983832 Anxa2 Annexin A2 6 
 46559406 Pak2 Serine/threonine-protein kinase PAK 2 4 
 124517663 Anxa1 Annexin A1 4 
 157951604 Cap1 Adenylyl cyclase-associated protein 1 3 
 13096922 Arhgap17 Rho GTPase-activating protein 17 2 
 13878195 Pik3ap1 Phosphoinositide 3-kinase adapter protein 1 3 
 11528490 Flii Protein flightless-1 homolog 4 
 123701966 Kctd12 BTB/POZ domain-containing protein 
KCTD12 
4 
 24025665 Plekho2 Pleckstrin homology domain-containing 
family O member 2 
4 
 123241346 Sh3bp1 SH3 domain-binding protein 1 3 
 1209068 Inpp5d Phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase 1 (Ship1) 
3 
 15489209 Themis2 THEMIS2 (Icb1) 2 
 123227481 Ybx1 Y box protein 1 2 
 124248570 G3bp2 GTPase activating protein (SH3 domain) 
binding protein 2 
2 
 225543183 Vwa5a von Willebrand factor A domain-containing 
protein 5A (Loh11cr2a) 
3 
 20138411 Ptk2b Protein-tyrosine kinase 2-beta 3 
 1915913 Dpysl2 Dihydropyrimidinase-related protein 2 3 
 192657 Ppp3ca Serine/threonine-protein phosphatase 2B 
catalytic subunit alpha isoform 
2 
 255003810 Rab3gap2 Rab3 GTPase-activating protein non-
catalytic subunit 
2 
 37590218 Abr Active breakpoint cluster region-related 
protein 
2 
 45597447 Sod1 Superoxide dismutase [Cu-Zn] 2 
 40675709 Syk Tyrosine-protein kinase (Syk) 2 
 309255 Gnai2 Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
2 
 19852058 Dscaml1 Down syndrome cell adhesion molecule-like 
protein 
2 
 6644338 Prdx5 Peroxiredoxin-5 2 
Innate Immunity 6754954 Sqstm1 Sequestosome 1 (p62) 6 
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 91064876 Gbp5 Guanylate binding protein 5 7 
 132252411 Ifih1 Melanoma differentiation-associated protein 
5 (MDA5) 
7 
 160333495 Gm14446 Gm14446 protein 8 
 213418055 Samhd1 SAM domain and HD domain-containing 
protein 1 (Mg11) 
5 
 15030162 Gbp2 Interferon-induced guanylate-binding protein 
2 
6 
 51702775 PPIA Peptidyl-prolyl cis-trans isomerase A 
(Cyclophilin A) 
4 
 115270958 Gvin1 Interferon-induced very large GTPase 1 2 
 70608133 Dhx58 Probable ATP-dependent RNA helicase 
DHX58 (LGP2) 
4 
 14861844 D1Pas1 Putative ATP-dependent RNA helicase Pl10 4 
 15489209 Themis2 THEMIS2 (Icb1) 2 
 23468336 Trafd1 FLN29 (TRAF-type zinc finger domain-
containing protein 1) 
3 
 6754994 Pcbp1 poly(rC)-binding protein 1 3 
 18044838 Zbp1 Z-DNA-binding protein 1 2 
 26326901 Ripk1 Receptor-interacting serine/threonine-protein 
kinase 1 
2 
 1698556 Ncf4 Neutrophil cytosol factor 4 (p40phox) 2 
 287323109 Hck Tyrosine-protein kinase HCK 2 
 114326482 Stat1 Signal transducer and activator of 
transcription 1 
7 
 13633965 Stat2 Signal transducer and activator of 
transcription 2 
8 
Vesicle Transport/ 
Phagocytosis 
15341745 Ehd4 EH-domain containing 4 15 
 13385878 Snx2 Sorting nexin 2 11 
 31543349 Nsf Vesicle-fusing ATPase 8 
 12248793 Snx1 Sorting nexin 1 7 
 51491845 Cltc Clathrin heavy chain 1 3 
 227116320 Fkbp15 FK506-binding protein 15 4 
 83649760 Wash1 WAS protein family homolog 1 3 
 22122347 Gga1 ADP-ribosylation factor-binding protein 
GGA1 
2 
 23956096 Uso1 General vesicular transport factor p115 2 
 22477515 Ehd1 EH-domain containing 1 2 
Protein Translation 26354649 Pabp1 Polyadenylate binding protein 1 13 
 13278382 Eef1a1 Elongation factor 1-alpha1 8 
 12963511 Rps19 40S ribosomal protein S19 9 
 200796 Rps16 40S ribosomal protein S16 10 
 3097244 Rps14 Ribosomal protein S14 7 
 6677775 Rpl22 60S ribosomal protein L22 5 
 1083569 Hnrnpk Heterogeneous nuclear ribonucleoprotein K 6 
 116517301 Ptbp1 Polypyrimidine tract binding protein 1 2 
 127798883 Cyfip1 Cytoplasmic FMR1-interacting protein 1 4 
 127799069 Syncrip Heterogeneous nuclear ribonucleoprotein Q 
(hnRNP Q) 
4 
 9506571 Eif2s1 Eukaryotic translation initiation factor 2 
subunit 1 
4 
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 118344452 Srp72 Srp72 2 
 11527388 Qki Protein quaking 3 
 13905140 Farsa Phenylalanine--tRNA ligase alpha subunit 3 
 118600514 Fam129a Niban 2 
 123235430 Srp14 Srp14 2 
Cytoskeletal 61743961 Ahnak AHNAK nucleoprotein isoform 1 37 
 114326446 Myh9 Myosin-9 28 
 227116327 Tln1 Talin 1 7 
 125347376 Flna Filamin A 12 
 7106439 Tubb5 Tubulin beta-5 chain 4 
 33620739 Myl6 Myosin light polypeptide 6 8 
 134288917 Dync1h1 Cytoplasmic dynein 1 heavy chain 12 
 148747189 Map4 Microtubule-associated protein 4 4 
 47124599 Diap1 Diap1 protein 5 
 149263685 Ahnak2 AHNAK2 2 
 127798883 Cyfip1 Cytoplasmic FMR1-interacting protein 1 4 
 118136288 Fmnl1 Formin-like protein 1 3 
 255069756 Myo1f Myosin IF 3 
 123207565 Dync1i2 Dynein cytoplasmic 1 intermediate chain 2 3 
 110625624 Tcp1 T-complex protein 1 subunit alpha 3 
 161086971 Capza1 F-actin-capping protein subunit alpha-1 2 
 6756085 Zyx Zyxin 2 
 148708988 Dsp Desmoplakin 2 
 22122795 Dync1li1 Dynein cytoplasmic 1 light intermediate 
chain 1 
2 
 21594742 Elmo1 Engulfment and cell motility protein 1 2 
 125987599 Cd2ap CD2-associated protein 2 
Ubiquitin/UBL 7710044 Keap1 Kelch-like ECH-associated protein 1 9 
 237820660 Ubr4 E3 ubiquitin-protein ligase UBR4 12 
 127139140 Trim21 E3 ubiquitin-protein ligase TRIM21 5 
 123264882 Rnf213 Ring finger protein 213 6 
 116283726 Psmd1 Psmd1 protein 5 
 6679501 Psmc1 26S protease regulatory subunit 4 4 
 15823094 Ubl4 Housekeeping protein DXS254E 4 
 31980712 Usp25 Ubiquitin carboxyl-terminal hydrolase 25 2 
 4507793 UBE2N ubiquitin-conjugating enzyme E2 N 3 
 257153392 Ufd1l Ubiquitin fusion degradation protein 1 
homolog 
3 
 6754724 Psmd7 26S proteasome non-ATPase regulatory 
subunit 7 
2 
 5031981 Psmd14 26S proteasome non-ATPase regulatory 
subunit 14 
2 
 19705424 Psmd3 26S proteasome non-ATPase regulatory 
subunit 3 
2 
 5353754 Ddb1 DNA damage-binding protein 1 2 
Protein Folding/  
Stress Response 
118490060 Hspa1a Inducible heat shock protein 70 8 
 118142832 Hsp90aa Hsp90aa protein 6 
 126723461 Cct8 T-complex protein 1 subunit theta 3 
 62948125 Cct6a Chaperonin containing Tcp1, subunit 6a 
(Zeta) 
3 
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 110625624 Tcp1 T-complex protein 1 subunit alpha 3 
 238814391 Cct7 Chaperonin subunit 7 (Eta), isoform CRA_a 2 
 5353754 Ddb1 DNA damage-binding protein 1 2 
Metabolism 1674501 Anpep Aminopeptidase N 3 
 1405933 Pkm Pyruvate kinase isozymes M1/M2 5 
 109734501 Hk3 Hk3 protein (hexokinase 3) 2 
 19527028 Hdlbp High density lipoprotein-binding protein 
(Vigilin) 
4 
 13529599 Ldha L-lactate dehydrogenase 3 
 110590524 Nampt Nicotinamide phosphoribosyltransferase 2 
 14250204 Mthfd1 C-1-tetrahydrofolate synthase, cytoplasmic 2 
 26347093 Pfkp 6-phosphofructokinase type C 2 
 52353955 Phgdh D-3-phosphoglycerate dehydrogenase 2 
Other 7242171 Pcna Proliferating cell nuclear antigen 2 
 27371140 Bag6 Bat3 protein 2 
 15079335 Snrpd3 Small nuclear ribonucleoprotein D3 2 
 
Resources: NCBI protein: http://www.ncbi.nlm.nih.gov 
      UniProtKB: http://www.uniprot.org/uniprot 
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Table 3.2. Regulation of BMM cytokine production by ISG15 in response to TLR 
stimulation. (negative or positive regulation, free or conjugation dependent)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TLR Stimulation IL-6 IL-10 TNFα IL-1β chemokine
pIC neg/Free neg/Free pos/Conj n.d. No diff
LPS pos/Conj neg/Conj No diff No diff No diff
Imiq+ATP n.d. n.d. n.d. neg/Conj n.d.
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Summary 
 
Although Chikungunya Virus was first described in 1952, very little was known about 
CHIKV until recently, due to increased attention brought about by the 2005 La Reunion outbreak 
(1, 2). During this outbreak, in addition to the classical symptoms of rash, joint pain and fever, 
novel symptoms were also reported, with increased severity in infants, elderly and the immune 
compromised (3-6). As the CHIKV epidemic grew, scientists recognized the need to learn more 
about the life cycle and host response to CHIKV, in the hopes of alleviating or preventing future 
CHIKV outbreaks. Our collaborators at the Pasteur Institute successfully developed a mouse 
model for CHIKV, allowing for initial studies on CHKV pathogenesis (7). As with other viruses, 
type I interferons (IFN) were shown to be vital for the control of CHIKV infection (7, 8). Type I 
IFN mediates antiviral protection through the upregulation of hundreds of IFN stimulated genes 
(ISGs) (9). However, the role of ISGs during CHIKV infection was largely unknown. In this 
thesis, we focused our efforts on learning more about CHIKV pathogenesis, in part by describing 
a role for the interferon stimulated gene ISG15.  
 Due to increased severity of disease symptoms in infants, we focused our attention on a 
neonatal model of CHIKV infection. Interestingly, although infants show increased severity, this 
is not due to a lack of a robust immune response. In Chapter 2, we demonstrate that both human 
infants and neonatal mice generate a robust type I IFN response during CHIKV infection. 
Signaling through the type I IFN receptor is at least partially intact, as we were able to detect 
IRF7, Mx1 and ISG15 mRNA induction at the site of infection in neonatal mice. In order to 
understand mechanistically how type I IFNs protect neonates from CHIK induced lethality, we 
evaluated a role for ISG15. 
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 A role for ISG15 in viral infection has been previously described. During Influenza B and 
Sindbis virus infections, ISG15 mediates protection through conjugation. ISG15
-/-
 mice and mice 
that lack the ability to form ISG15 conjugates, UbE1L
-/-
, phenocopy each other and show 
increased viral loads compared to WT mice. During CHIKV infection, we also show that ISG15
-
/- 
mice have increased susceptibility to viral induced lethality. We were surprised to find, 
however, that UbE1L
-/-
 mice phenocopy WT mice during CHIKV infection. We also found that 
ISG15
-/-
 mice did not have increased viral loads compared to WT mice. Instead, we observed an 
increase in pro-inflammatory cytokines and chemokines in ISG15
-/-
 mice. Altogether, this data 
suggested that the mechanism by which ISG15 protects against CHIKV infection is different 
from the antiviral role described for ISG15 during both influenza B and Sindbis virus models. 
UbE1L is the only identified E1 for ISG15 and we were unable to detect ISG15 conjugates in 
CHIKV infected UbE1L
-/-
 mice. Therefore, we hypothesized that the role of ISG15 during 
CHIKV infection is conjugation independent and occurs through the regulation of the host 
response to viral infection. 
 To provide additional support for a role for unconjugated ISG15 during CHIKV 
infection, we generated recombinant Chikungunya viruses that expressed wild type or 
conjugation deficient ISG15, where the C-terminal LRLRGG motif necessary for conjugation 
has been mutated to LRLRAA (CHIK-GG and CHIK-AA, respectively). This strategy was 
previously employed during Sindbis virus infection, where a LRLRGG expressing recombinant 
Sindbis virus could rescue ISG15
-/-
 from lethality, whereas conjugation deficient ISG15 
expressing Sindbis could not (10, 11). Once again we were surprised by our results, as we could 
not rescue ISG15
-/-
 mice with the CHIK-GG expressing virus. There several possibilities as to 
why we were unable to provide protection, including insufficient levels of ISG15 expression or 
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ISG15 may not be stably expressed. Our data may also suggest that ISG15 is not expressed in the 
right cell type or the expression of ISG15 is required in an uninfected cell. Although there are 
several possibilities as to why our wild type ISG15 recombinant virus was unable to rescue 
ISG15
-/-
 mice, we hypothesize that this also hints at a novel mechanism for ISG15. 
 Taken together, our data indicates that ISG15 functions by a previously unidentified 
mechanism to control the host response to CHIKV. Free ISG15, not the conjugated form, 
appears to be necessary for protection. We also hypothesize from our recombinant CHIKV 
model that ISG15 functions in an uninfected cell. Unlike previous models (10, 12), ISG15 is not 
directly antiviral, but instead regulates the host immune response.  
 Unanchored ISG15 can be found within a cell and can also be detected in the serum of 
infected mice. In order to determine how ISG15 protects against CHIKV infection, we decided to 
characterize both intra- and extracellular free ISG15. Cytokine activity for extracellular ISG15 
has been reported and unanchored polyubiquitin chains regulate signaling within cells (13-18). In 
Chapter 3, we identify phosphorylation as a possible post-translational modification for serum 
ISG15. We also identify the 30kDa ISG15 serum band as ISG15 bound to hemoglobin subunit 
beta 1. The consequences of phosphorylation and the functional role of the 30kDa conjugate are 
unknown. We hypothesize that for either form of serum ISG15 to have activity, they must signal 
through an unidentified ISG15 cell surface receptor. 
 To identify non-covalent binding partners for ISG15, we used a recombinant tagged 
ISG15 construct for immunoprecipitation studies. Through mass spectrometry, we were able to 
identify over 140 potential binding partners for intracellular ISG15. Similar to ISGylation, non-
covalent binding partners for ISG15 appear to be involved in multiple cellular pathways, 
including innate immunity, stress response, vesicle sorting, cytoskeletal and cell signaling. We 
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compared conjugation targets to free ISG15 targets and identified some proteins that did overlap 
(STAT1, Annexin) (19, 20). However, for the most part, the proteins that we identified 
represented novel targets. We found two proteins that were also identified in a Y2H screen 
performed by Nadia Giannakopoulos: PCBP1 (poly(C) binding protein 1) and Clathrin 
(unpublished data), which may be promising targets. The hits that we have identified need to be 
verified, although we have begun this process by demonstrating that ISG15 can co-ip with 
MDA5. 
 One of the mechanistic clues that we gained from our CHIKV model was the increased 
pro-inflammatory cytokine production in ISG15
-/-
 mice. Therefore, we began preliminary 
investigations into ISG15s ability to regulate cytokine production. We demonstrate that ISG15 
has the ability to regulate cytokine production following TLR stimulation and show that free 
ISG15 can regulate IL-6 production in response to pIC. We noted that both pIC and CHIKV can 
signal through MDA5, a potential non-covalent partner for ISG15. Whether increased cytokine 
production in response to pIC is due to ISG15s participation in the MDA5 pathway remains to be 
determined. We found that ISG15s ability to regulate cytokine production is complex, as the 
cytokine profile produced was dependent on both the type of stimulation and the type of cell. 
 Altogether, our most significant finding is that ISG15 regulates CHIKV infection 
independent of UbE1L mediated conjugation. This provides a unique opportunity to identify a 
mechanism of action for free ISG15. To meet this end, we have characterized both intra- and 
extracellular ISG15 and have begun functional studies relative to our mass spec results and our 
CHIKV model. It is our hope that our findings will not be specific to CHIKV, but will aid our 
overall understanding of ISG15s activity as an important effector of the type I IFN response.  
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Future Directions 
 
Although we and others have taken important steps to characterize ISG15, the mechanism(s) by 
which ISG15 protects against viral infection is still largely unknown. Below we discuss future 
experiments that may aid in this discovery. 
 
Is there a cell surface receptor for ISG15? 
 Extracellular ISG15 is found in the serum of virally infected mice and has been reported 
to have cytokine like activity. Stimulation with recombinant ISG15 results in NK cell 
proliferation, neutrophil recruitment, and dendritic cell maturation (13-15). Importantly, a recent 
report identifying ISG15 null mutations in humans has shown that recombinant ISG15 has the 
ability to regulate cell mediated IFNγ production in concert with IL-12 (16). How ISG15 
mediates these activities is not understood, although we hypothesize that it is dependent on 
ISG15s ability to bind to an unidentified cell surface receptor.  
Jessea Campbell has initiated preliminary investigations into identifying a receptor for 
ISG15. Our main goal is to generate recombinant ISG15, identify cells that can bind ISG15, and 
then generate a cDNA expression library to search for a possible receptor. We started by staining 
splenocytes from pIC stimulated mice with Fc-tagged mISG15 (Fc empty vector and DIII-Fc as 
negative controls). Unfortunately, results using Fc tagged versions of ISG15 were inconclusive. 
Innate immune cells, possibly neutrophils or CD8 dendritic cells, stained positive for ISG15, 
whereas B and T cells were negative. Primary BMM and BMDCs as well as the macrophage 
RAW cell line also bound ISG15-Fc (data not shown). Fc empty vector showed no binding and 
DIII Fc binding was lower than ISG15-Fc. Interestingly, pretreatment of RAW cells increased 
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the amount of ISG15-Fc binding. We hypothesize that, similar to the ISG15 conjugation cascade, 
the ISG15 receptor may be induced. However, when we generated a mutant Fc that could not 
bind Fc receptor, ISG15 binding was lost. This data suggests that our initial findings were 
dependent on Fc binding, although it is unclear why there remained a difference between non-
mutant DIII and ISG15 constructs. As an alternative approach, we have generated BirA tagged 
ISG15 for the generation of ISG15 tetramers for use in similar experiments.  
We hypothesize that innate hematopoietic cells are likely candidates for expression of an 
ISG15 receptor, as ISG15s activity has been reported for these cells in the literature and they 
play an important role in the initial response to viral infection when ISG15 is first expressed. 
Although we have not determined whether ISG15 mediated protection during CHIKV infection 
is dependent on intra- or extracellular ISG15, we propose that resident non-hematopoietic cells 
(i.e. muscle fibroblasts) should also be investigated, as Schlite et al has demonstrated that IFN 
mediated control of CHIKV infection is dependent on non-hematopoietic cells (8). 
Generation of recombinant ISG15- mutant Fc for our intracellular mass spec studies as 
well as our cell surface staining provided a potential useful tool for investigating the functional 
consequences of extracellular ISG15 stimulation. To investigate a role for extracellular ISG15, 
we pre and/or post treated ISG15
-/-
 primary BMM and muscle fibroblasts with recombinant 
ISG15 and then stimulated with pIC. Supernatant was collected and assayed for cytokine 
production via bioplex. Unfortunately, the conditions used to generate the recombinant protein 
included a contaminant that led to non-specific activation of BMM, masking any potential ISG15 
activity (data not shown). Interestingly, primary muscle fibroblasts did not have non-specific 
activation and we observed that pretreatment of these cells dramatically decreased the amount of 
IL-6 produced in response to pIC (Fig. 4.1). These results were dependent on high concentrations 
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of ISG15, therefore it is unclear whether our results are physiologically relevant. However, this 
data may suggest that (1) primary muscle fibroblasts can respond to extracellular ISG15 and (2) 
extracellular ISG15 may negatively regulate IL-6 production.    
To verify functional readouts for ISG15, data would be strengthened by having the ability 
to block extracellular ISG15 activity. We have attempted to block extracellular ISG15 activity in 
WT neonates during CHIKV infection by administering a rabbit anti-ISG15 polyclonal antibody 
24hrs prior to infection. Unfortunately, our antibody pretreatment did not impact the survival, 
viral loads, or cytokine production in WT mice (Fig 4.2). There are many potential explanations 
for why our αISG15 antibody could not protect, such as inability of the antibody to block 
activity, insufficient amount to block activity, or maybe blocking was successful, but 
extracellular ISG15 is not essential during CHIKV infection. To verify the ability of our ISG15 
antibody to block extracellular ISG15 activity, we must first establish a functional readout 
(preferably in vitro) for recombinant ISG15 stimulation.   
Many additional questions need to be addressed to confirm an activity for extracellular 
ISG15. We do not know how much ISG15 is released following IFN stimulation or viral 
infection. We also do not know whether release of ISG15 is an active process or due to release 
from dead or dying cells. If ISG15 secretion is active, what cells are responsible for release of 
ISG15 during in vivo viral infection? Interestingly, during influenza B chimeric bone marrow 
studies, ISG15 was found in the serum of WT > ISG15
-/-
 infected mice but not ISG15
-/- 
> WT 
mice by western blot analysis, suggesting that (1) ISG15 release is an active process and (2) 
ISG15 may be secreted from hematopoietic cells (data not shown). 
 In summary, finding an activity for extracellular ISG15 is dependent on further 
characterization of serum ISG15 (post translational modifications (Chapter 3), mechanism of 
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secretion, physiological levels) as well as identification of an ISG15 receptor. Once these 
parameters have been established, functional relevance may be derived by identifying ISG15-
ISG15 receptor binding interactions and potential downstream signaling consequences.  
 
Confirmation of non-covalent binding partners for intracellular ISG15 
We believe that our identification of non-covalent binding partners for intracellular 
ISG15 is a promising start to finding mechanisms for both free and conjugated ISG15. We 
recognize, however, that many of the proteins that we have identified using mass spectrometry 
may not directly bind ISG15. To confirm binding partners for ISG15, we have begun initial 
overexpression co-ip studies using a 293 transfection system. If proteins can be verified via 
overexpression, similar co-ip studies can be used to establish endogenous interactions. 
Additional mutagenesis analysis will allow for identification of domains and/or residues that are 
responsible for ISG15 binding, which may aid in future functional studies. Strength and kinetics 
of binding may also be evaluated using recombinant proteins and such techniques as Surface 
Plasma Resonance (SPR).  
We note that we did not identify any transmembrane proteins from our mass spec 
analysis. It is possible that the conditions that we used to generate cytosol from BMM did not 
allow for isolation of transmembrane proteins. We also note that our mass spec hits are specific 
for IFN/pIC stimulated BMM, therefore may not represent additional binding partners in 
different cells or in response to other forms of stimulation (TLR4, inflammasome, etc). 
Therefore, our results most likely do not represent the full repertoire of ISG15 binding partners 
but may be used to direct attention to certain cell signaling pathways.     
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We hypothesize that like ubiquitin, non-covalent ISG15 may be recognized by proteins 
that contain an unknown “ISG15 binding domain” (ISGBD). This ISGBD may contain sequence 
similarities with ubiquitin binding domains (21, 22). We also hypothesize that ISG15 can 
compete with ubiquitin for binding to known ubiquitin binding domains. Therefore, we searched 
our non-covalent mass spec results (Table 3.1) for conserved protein binding domains. 
Interestingly, so far we have only identified three ubiquitin binding domains that unfortunately, 
are not shared by any of our other mass spec hits: UBA (p62), VHS (Gga1) and UIM (Usp25). 
Blast searches of portions of these ubiquitin binding domains within functional categories did not 
reveal a conserved amino acid sequence shared between mass spec hits. These results are 
preliminary and may improve by decreasing the stringency of our Blast searches or by 
eliminating proteins on our mass spec list that do not bind ISG15. We suggest that mutagenesis 
of a known ISG15 interacting partner may be the best approach for identifying an ISG15 binding 
domain.  
 
What are the functional consequences for intracellular ISG15s non-covalent interactions?    
 From our mass spec analysis, we have identified proteins involved in many different 
intracellular pathways, including innate immunity, vesicle sorting, protein translation, cell 
metabolism and cell signaling pathways. If we are able to confirm ISG15 binding, we will need 
to demonstrate the functional consequences of this interaction. In Chapters 3, we have 
highlighted MDA5, a known ubiquitin binding protein, as a promising candidate for ISG15 
binding activity. Below we briefly examine a few other candidates that may relate to our 
observations during CHIKV infection.      
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 NCF4 (neutrophil cytosolic factor 4), also known as p40phox, is a member of the 
NADPH oxidase. The NADPH oxidase is responsible for the generation of reactive oxygen 
species (ROS) that play an important role in macrophage activation and inflammation (23). 
p40phox is one of six subunits that makes up the NADPH oxidase and is known to regulate 
NADPH oxidase activity in vivo (23). To our knowledge, the contribution of ISG15 to ROS 
generation has not been evaluated. Our ability to generate primary knockout cells may allow for 
the development of an in vitro model to assess whether or not ISG15 can influence ROS 
production.  
Poly (C) binding protein 1 (PCBP1) was one of the few mass spec hits that was also 
identified in Nadia’s Y2H screen. Poly (C) binding proteins represent a family of RNA-binding 
proteins with high affinity and sequence specific interaction with poly(C) (24). PCBPs are 
involved in multiple cellular processes and have been shown to regulate mRNA stability, 
transcription and translation. Importantly, PCBP1 and PCBP2 have been shown to mediate the 
degradation of MAVs through the recruitment of the E3 ubiquitin ligase AIP4 (25, 26). To assess 
a role for PCBP1, we may evaluate ISG15s ability to regulate MAVs degradation or MAVs 
downstream signaling. 
We have also identified several proteins involved in vesicle sorting, including Sorting 
Nexins 1 and 2 (Snx1/2), general vesicular transport factor p115 (Uso1), and clathrin heavy 
chain 1. The mechanism by which ISG15 is secreted is unknown, therefore we hypothesize that 
ISG15s ability to interact with members of vesicular transport may reveal how ISG15 is released. 
Knockdown of these sorting proteins may be used to evaluate the importance of these proteins in 
ISG15 secretion. We recognize that vesicular sorting proteins play additional roles besides 
protein secretion, including membrane remodeling, cell surface receptor recycling and retrograde 
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transport from endosomes to the Trans Golgi network (TGN) (27, 28). A potential role for ISG15 
in these pathways is unclear.    
 Another protein that we have identified, p62, also has the capability to bind to both mono 
and polyubiquitin. As we have generated preliminary data examining a role for ISG15 in 
autophagy and apoptosis, we will discuss these pathways in more detail in the following section.  
 
A quick look at ISG15 and Autophagy/Apoptosis (includes excerpt from Joubert et al 
2012). 
Past research has shown that both apoptosis and autophagy are induced during Sindbis 
virus infection and manipulation of either of these cellular pathways can alter Sindbis disease 
progression (29-31). Our collaborators at the Pasteur Institute demonstrate that autophagy is 
induced during CHIKV infection and acts in part by limiting apoptosis induction (32). We also 
demonstrate that autophagy is necessary for in vivo protection against CHIKV induced lethality. 
To analyze the potential role of autophagy in CHIKV pathogenesis we used Atg16L 
hypomorphic mice (Atg16LHM) in which Atg16L1 gene has been modified by gene trap 
mutagenesis. These mice display hypomorphic expression of Atg16L protein and reduced 
autophagy (not depicted; (33)). 9-d-old WT and Atg16LHM mice were infected with CHIKV 
and followed for lethality (Fig. 4.3A). Although only 60% of WT mice succumbed to CHIKV, 
we observed an increase in lethality in Atg16LHM mice. These data indicate that autophagy has 
a pro-survival function during CHIKV infection and limits disease pathogenesis. To understand 
how autophagy enhances survival, we analyzed viral load in infected tissues in WT and 
Atg16LHM mice (Fig. 4.3B). Viral load in skin muscle and serum, important targets of CHIKV 
infection, were similar in WT and Atg16LHM mice, suggesting that autophagy did not 
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significantly affect in vivo viral infection. Similar results were obtained by analyzing the viral 
load in lung, liver, brain, and spleen (unpublished data). Interestingly, the one observed 
difference concerned a delayed clearance of CHIKV in the muscle at day 9 after infection. 
Joubert et al go on to show that CHIKV Atg16LHM mice display increased levels of caspase 3 
activation compared to WT mice despite similar viral loads (data not shown)(32). Our data 
indicates that autophagy limits apoptotic induction of CHIKV infected tissues and delays 
lethality of mice.   
 The ability of ISG15 to regulate autophagy and/or apoptosis is unknown, although we 
hypothesize that if ISG15 can regulate autophagy/apoptosis, then increased lethality observed in 
ISG15
-/-
 mice during CHIKV infection may result from altered regulation of these two pathways. 
Analysis of LC3 and p62 conversion following autophagy induction in vitro did not reveal a role 
for ISG15 (Fig. 4.4). WT, UbE1L
-/-
 and ISG15
-/-
 MEFs and BMM were treated with EBSS 
(serum starvation) or Rapamycin/Chloroquine to induce autophagy (33, 34), with or without 
IFNβ pretreatment. Autophagy induction was assessed by examining LC3-II and p62 
accumulation in cell lysates 1-9hrs post stimulation via western blot analysis. Baseline levels of 
LC3-II and p62 were equivalent between untreated WT, UbE1L
-/-
 and ISG15
-/-
 MEFs. IFNβ 
pretreatment only slightly increased observed levels of LC3-II and p62 above baseline. 
Treatment with rapamycin and chloroquine post IFNβ treatment greatly increased the amount of 
LC3-II and p62 above baseline, however there was no difference between the three genotypes 
(Fig. 4.4A). BMM behaved similarly to MEFs (Fig. 4.4B). ISG15 expression in IFNβ stimulated 
cells was also confirmed by western blot analysis. Under these conditions, we were unable to 
describe a role for ISG15 in autophagy. We hypothesize that ISG15 may not regulate overall 
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autophagy protein levels, but may impact the delivery of cellular components to the 
autophagosome.   
Although a role for ISG15 in apoptosis/autophagy has not been described, ubiquitin is 
known to play an important role in both of these pathways. Both mono-ubiquitin and 
polyubiquitin chains are important molecular tags for targeting intracellular protein aggregates, 
organelles as well as intracellular pathogens for autophagy (35). Ubiquitinated targets are 
recognized by autophagy adaptor proteins, primarily p62 and NBR1, which deliver their 
ubiquitinated targets to the autophagosome. These autophagy adaptor proteins have been termed 
SLRs (sequestosome 1/p62-like receptors) and represent a newly recognized class of pattern 
recognition receptors that link autophagy to inflammation and other innate immune pathways 
(35). From our mass spec analysis, we have identified p62 as a potential binding partner for 
ISG15 (Chapter 3). Therefore, we hypothesize that, similar to ubiquitin, ISGylated proteins can 
be recognized by p62 and somehow influence the autophagy pathway. Alternatively, free ISG15 
may bind to p62 and inhibit its ability of p62 to bind ubiquitinated cargo. The consequences of 
ISG15s binding to p62 remains to be investigated, but represents an exciting opportunity for 
identifying a novel function for ISG15. Through mass spec, we have also identified the p62 
interacting protein Keap1 (36, 37), which may also warrant future study.  
Ubiquitin has also been shown to play a role in apoptosis, although its role is primarily 
dependent on ubiquitylation of target proteins for the proteasome (38). We have also begun 
preliminary investigations into ISG15 and apoptosis. No difference in cell viability have been 
observed under normal growth conditions for WT, UbE1L
-/-
 and ISG15
-/-
 primary cells (BMM, 
BMDC, MEFs, muscle fibroblasts) in vitro. Altering the conditions of in vitro cell growth, by 
treatment with IFNβ, pIC or viral infection has also not generated a difference in cell viability, 
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although these results have not been closely quantitated or documented. To assess a role for 
ISG15 in apoptosis during CHIKV infection, we stained CHIKV infected skin and muscle tissue 
from WT, UbE1L
-/-
, and ISG15
-/-
 neonates with anti-caspase 3 antibody ((Fig. 4.5), staining and 
analysis done with the help of Pierre-Emmanuel Joubert). Strikingly, ISG15
-/-
 show increased 
levels of caspase 3 staining during CHIKV infection compared to WT and UbE1L
-/-
 mice. We 
have previously demonstrated that WT, UbE1L
-/-
 and ISG15
-/-
 mice do not display differences in 
skin/muscle viral titers. This suggests that the increase in apoptosis is not due to increased viral 
burden in ISG15
-/-
 mice, however this was not directly shown for the caspase3 samples as anti-
CHIK staining was unsuccessful. Future studies are necessary to establish a role for ISG15 in 
apoptosis.  
 
Alphaviruses and ISG15: To conjugate or not to conjugate? 
 Sindbis virus (SINV) is an alphavirus that is closely related to CHIKV. Like CHIKV, 
SINV is an Old World alphavirus that is arthogenic, although neuroadapted strains of SINV have 
been described (39). As the role of ISG15 during SINV infection is conjugation dependent (11), 
we were surprised when we discovered that ISG15s role during CHIKV infection was not 
mediated by UbE1L. This UbE1L independent mechanism of ISG15 was not specific to CHIKV, 
as we demonstrated a similar phenotype for additional alphaviruses: RRV and BFV. We do not 
understand why ISG15 mediated restriction of some viruses is conjugation dependent while for 
others, it appears to be conjugation independent. We hypothesize that viral determinants may 
dictate how ISG15 mediates its protective effects. The similarities between SINV and CHIKV 
may provide a unique opportunity to identify which viral proteins influence ISG15 restriction, if 
this is indeed the case. The generation of chimeric viruses is a common vaccine strategy, and has 
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been demonstrated with CHIKV using TC-83 and Sindbis virus backbones (40). Therefore, we 
propose domain swap studies between SINV and CHIKV to determine if ISG15s conjugation 
restriction can be tied to an individual or set of viral proteins.      
 
What is the role for ISG15 in cytokine production? Does ISG15 regulate cytokine 
production in response to other stimuli? 
 Type I IFNs impact the function of both innate and adaptive immunity. IFN production 
leads to activation of DCs and NK cells and also promotes the survival and effector function of B 
and T cells (9). It is thought that one of the mechanisms by which IFN alters an immune 
response is through the regulation of cytokine production. Indeed, IFNs anti-inflammatory 
properties have been used therapeutically for autoimmune or inflammatory disorders, including 
multiple sclerosis (MS) (41). Recent research suggests that type I IFN inhibits IL-1β production 
and inflammasome activation (42). Although IFN has been suggested to regulate cytokine 
production, the mechanism of action is still largely unknown. Due to our CHIKV phenotype, we 
hypothesized that ISG15 may be a downstream effector of IFN mediated cytokine regulation.    
ISG15
-/-
 mice during CHIKV infection display elevated proinflammatory cytokine levels 
compared to UbE1L
-/-
 and WT mice. The levels of TNF observed were similar to that observed 
in some adult models of LPS induced septic shock (43, 44) as well as neonatal Sindbis virus 
infections (45), where mice are thought to die from a cytokine storm. Necropsy analysis revealed 
that ISG15
-/-
 mice had more severe blood vessel and airway injury than WT and UbE1L
-/-
 mice. 
ISG15
-/-
 mice also had altered blood chemistry, which may indicate multiple organ dysfunction, 
another potential readout for septic shock (Fig S2.5). We hypothesize that the cytokine increase 
in vivo may contribute to the increased lethality observed in ISG15
-/-
 mice during CHIKV 
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infection and suggest that ISG15s ability to regulate cytokine production is biologically 
significant. 
   As ISG15 appears to impact cytokine production during CHIKV infection, we 
investigated cytokine production in ISG15
-/-
 in response to other stimuli. Our lab has previously 
shown that the role of ISG15 during influenza B virus infection is conjugation dependent. 
ISG15s action is also directly antiviral, as UbE1L
-/- 
and ISG15
-/-
 mice show elevated influenza B 
titers compared to WT mice (Fig 4.6A)(12). Interestingly, although conjugation appears to be 
essential for protection against influenza B, analysis of cytokines produced indicates a 
mechanism of action for free ISG15 during influenza B infection. UbE1L
-/-
 and ISG15
-/-
 mice 
have equivalent viral loads during influenza B infection, however, as with CHIKV, ISG15
-/-
 mice 
display a marked increase in pro-inflammatory cytokine production (Fig 4.6B). We suggest that 
although this cytokine increase does not appear to contribute to the lethality of ISG15
-/-
 mice, the 
mechanism of free ISG15 mediated cytokine regulation is still conserved in this influenza B 
model. We note that one of the key differences between our influenza B and CHIKV models is 
the age of the mice: CHIKV is neonates and influenza B is adults. We speculate that adult mice 
are more resistant to cytokine increases, therefore influenza B infected ISG15
-/-
 mice do not 
show an increase in lethality compared to UbE1L
-/- 
mice. Indeed, our CHIKV model is also age 
dependent, as older ISG15
-/-
 mice are considerably more resistant to CHIK induced lethality 
compared to our 9day old model.  
 In Chapter 3, we demonstrate that ISG15 can regulate cytokine production in response to 
pIC stimulation. Interestingly, unlike pIC stimulation or CHIKV infection, LPS treatment leads 
to a different pattern of cytokine production (Table 3.2). Following LPS treatment, ISG15
-/- 
mice 
and cells show a decrease in IL-6 production. In addition to pIC and LPS, we also tried 
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inflammasome activation to evaluate IL-1β production. Although preliminary, our data might 
suggest that inflammasome mediated IL-1β production is regulated by ISG15 conjugation. 
Altogether, regulation of cytokine production by ISG15 is complex and appears to be dependent 
on the type of PRR stimulation. 
   
Bridging Free and Conjugated ISG15: The Molecular Tag Hypothesis. 
 Although the focus of this thesis has been on free ISG15, we hypothesize that the non-
covalent binding properties of free ISG15 may be necessary for the function(s) of conjugated 
ISG15. From western blot analysis, we normally observe that only a small percentage of a target 
proteins become ISGylated. One of the underlying questions in the field of ISG15 is if only a 
small percentage of protein gets modified, how can this have a functional consequence? A theory 
has been proposed by (46) based on their observation that the primary E3 for ISG15, Herc5, 
associates with ribosomes. They hypothesize that ISG15 non-discriminately labels newly 
translated proteins and modification of host proteins is “collateral damage.” Viral proteins are 
proposed to be the actual targets of ISGylation and modification of structural proteins inhibits the 
ability of a virus to form a mature virion due to steric hindrance, thus inhibiting viral replication. 
This would require that only a fraction of viral proteins gets modified, consistent with most 
observations. 
 We wish to extend this theory and propose that ISG15 tags viral proteins for 
identification by host proteins. During viral assembly, we hypothesize that ISGylated viral 
proteins are recruited to the viral replication complex. Host proteins can then bind and recognize 
ISGylated proteins via non-covalent interactions or a hypothetical ISG15 binding domain. This 
allows for recruitment of host proteins to the viral replication complex and requires that only a 
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small number of viral proteins become modified. For example, we hypothesize that p62 (one of 
our mass spec hits) recognizes and binds to ISGylated proteins and targets them for destruction. 
P62 is recruited to the viral replication complex, allowing for autophagosome formation around 
the viral replicon for targeted destruction. We hypothesize that other host proteins may also be 
recruited via a similar mechanism. Another similar theory is that mature virions may be 
ISGylated, allowing for recognition by the unidentified ISG15 receptor and 
internalization/destruction of the released virus. Although we hypothesize that the “collateral 
damage” theory may be valid, we also recognize the potential of ISG15 to serve as an adaptor 
between host proteins. Therefore, ISG15 regulation of viral replication may be dependent on (1) 
ISG15 conjugation and (2) recognition of ISGylated proteins via ISG15 binding proteins. Future 
studies are required to establish a relationship between free and conjugated ISG15.      
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Figure 4.1. Pretreating ISG15
-/- 
muscle fibroblasts with recombinant ISG15 results in 
decreased IL-6 production.  ISG15
-/- 
primary muscle fibroblasts were pretreated with 1-5 
ug/mL recombinant ISG15 -mutant Fc or DIII –mutant Fc protein. 24hrs after ISG15 
pretreatment, cells were stimulated with 10ug pIC  along with (prepost) or without (pre) 1-5ug 
ISG15. Cell supernatants were harvested 18hrs post treatment and IL-6 was measured via 
Bioplex. Representative of two different experiments (N=2).    
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Figure 4.1 
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Figure 4.2. Pretreatment of WT mice with a polyclonal anti-ISG15 antibody did not impact 
survival, viral titers or cytokine production during CHIKV infection. (A) Nine day old WT 
mice were pretreated with 30uL of anti-ISG15 rabbit polyclonal sera (1552) 24hrs before 
infection with 10
5
 PFU CHIKV s.c. Survival was followed for 21 days and compared to 
untreated WT mice. (B and C) In a separate experiment, WT mice were pretreated with anti-
ISG15 or a non-specific antibody (1781) 24hrs before CHIKV infection. Skin/muscle from the 
site of infection as well as serum was collected on days 1 and 2 post infection. Viral titers were 
determined by plaque assay and serum cytokine levels were measured via bioplex.  
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Figure 4.2 
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Figure 4.3. Autophagy limits apoptotic induction in CHIKV infected tissues and delays 
lethality of mice (Joubert et al 2012). (A&B) WT (n = 43) and Atg16L
HM
 mice (n = 34) were 
infected at 9 d of age with 4 × 10
5
 PFU CHIKV subcutaneously. (A) Mice were monitored for 
lethality for 21 d with data displayed as Kaplan-Meier curves. (B) Skin, muscle, and serum were 
collected after days 1, 2, 5, and 9 of infection, homogenized, and viral titers were determined by 
standard plaque assay. Median values for WT (black bars) or Atg16L
HM 
(blue bars) mice are 
depicted. 
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Figure 4.3 
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Figure 4.4. ISG15 does not appear to regulate total p62 and LC3-II levels following 
autophagy induction (preliminary data). (A) WT, UbE1L
-/- 
and ISG15
-/- 
MEFs were pretreated 
with IFNβ and then stimulated with rapamycin and chloroquine (RC). LC3-II, p62, and ISG15 
expression 8hrs post RC stimulation were identified by western blot analysis. (B) Activated WT, 
UbE1L
-/- 
and ISG15
-/- 
primary BMM were treated with EBSS or RC. LC3-II and ISG15 
expression 9hrs post autophagy induction were identified by western blot analysis (p62 was not 
detected). Similar results were obtained for earlier timepoints (2-6hrs) for both BMM and MEFs.  
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Figure 4.4 
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Figure 4.5 CHIKV infected ISG15
-/- 
mice may have elevated levels of apoptosis at the site of 
infection compared to WT and UbE1L
-/- 
mice (preliminary data in collaboration with 
Pierre-Emmanuel Joubert). Nine day old WT, UbE1L
-/- 
and ISG15
-/- 
mice were infected at with 
4 × 10
5
 PFU CHIKV s.c. Skin/muscle from the site of infection was collected on day 2 p.i. 
Tissue was fixed in PFA, frozen in OCT blocks, and stained for cleaved capsase-3. Each bar 
represents an individual mouse. Number of caspase 3 positive cells was counted from three 
separate sections for each mouse.   
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Figure 4.5 
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Figure 4.6. Influenza B infected ISG15
-/- 
mice have elevated cytokine and chemokine levels 
compared to UbE1L
-/- 
mice despite similar viral loads (Dr. Deborah Lenschow). WT, 
UbE1L-/- and ISG15-/- adult mice were infected with influenza B virus. (A) Lung viral titers 
were determined on days 3 and 6 post infection via plaque assay. (B and C) Serum cytokine (B) 
and chemokine (C) levels were assessed by bioplex on day 6 post infection. 
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Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 6
0
250
500
750
1000
1250
1500
IL-6    IFNg     IL-1    IL-13     IL-10
WT
ISG15-/-
UBE1L-/-
p
g
/m
l
Day 6
0
1000
2000
3000
4000
4000
6000
8000
  Rantes   MIP-1a  MIP-1b  MCP-1     KC
WT
ISG15-/-
UBE1L-/-
(p
g
/m
l)
A
B C
173 
 
 References 
 
1. Bessaud, M., C. N. Peyrefitte, B. A. Pastorino, F. Tock, O. Merle, J. J. Colpart, J. S. 
Dehecq, R. Girod, M. C. Jaffar-Bandjee, P. J. Glass, M. Parker, H. J. Tolou, and M. 
Grandadam. 2006. Chikungunya virus strains, Reunion Island outbreak. Emerg Infect Dis 
12:1604-1606. 
 
2. Her, Z., Y. W. Kam, R. T. Lin, and L. F. Ng. 2009. Chikungunya: a bending reality. 
Microbes Infect 11:1165-1176. 
 
3. Economopoulou, A., M. Dominguez, B. Helynck, D. Sissoko, O. Wichmann, P. Quenel, 
P. Germonneau, and I. Quatresous. 2009. Atypical Chikungunya virus infections: clinical 
manifestations, mortality and risk factors for severe disease during the 2005-2006 
outbreak on Reunion. Epidemiol Infect 137:534-541. 
 
4. Lemant, J., V. Boisson, A. Winer, L. Thibault, H. Andre, F. Tixier, M. Lemercier, E. 
Antok, M. P. Cresta, P. Grivard, M. Besnard, O. Rollot, F. Favier, M. Huerre, J. L. 
Campinos, and A. Michault. 2008. Serious acute chikungunya virus infection requiring 
intensive care during the Reunion Island outbreak in 2005-2006. Crit Care Med 36:2536-
2541. 
 
5. Ernould, S., H. Walters, J. L. Alessandri, B. Llanas, M. C. Jaffar, S. Robin, T. Attali, D. 
Ramful, and J. C. Combes. 2008. [Chikungunya in paediatrics: epidemic of 2005-2006 in 
Saint-Denis, Reunion Island]. Arch Pediatr 15:253-262. 
 
6. Gerardin, P., G. Barau, A. Michault, M. Bintner, H. Randrianaivo, G. Choker, Y. Lenglet, 
Y. Touret, A. Bouveret, P. Grivard, K. Le Roux, S. Blanc, I. Schuffenecker, T. Couderc, 
F. Arenzana-Seisdedos, M. Lecuit, and P. Y. Robillard. 2008. Multidisciplinary 
prospective study of mother-to-child chikungunya virus infections on the island of La 
Reunion. PLoS Med 5:e60. 
 
7. Couderc, T., F. Chretien, C. Schilte, O. Disson, M. Brigitte, F. Guivel-Benhassine, Y. 
Touret, G. Barau, N. Cayet, I. Schuffenecker, P. Despres, F. Arenzana-Seisdedos, A. 
Michault, M. L. Albert, and M. Lecuit. 2008. A mouse model for Chikungunya: young 
age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS 
Pathog 4:e29. 
 
8. Schilte, C., T. Couderc, F. Chretien, M. Sourisseau, N. Gangneux, F. Guivel-Benhassine, 
A. Kraxner, J. Tschopp, S. Higgs, A. Michault, F. Arenzana-Seisdedos, M. Colonna, L. 
Peduto, O. Schwartz, M. Lecuit, and M. L. Albert. 2010. Type I IFN controls 
chikungunya virus via its action on nonhematopoietic cells. J Exp Med 207:429-442. 
 
9. Paun, A., and P. M. Pitha. 2007. The innate antiviral response: new insights into a 
continuing story. Adv Virus Res 69:1-66. 
 
174 
 
10. Lenschow, D. J., C. Lai, N. Frias-Staheli, N. V. Giannakopoulos, A. Lutz, T. Wolff, A. 
Osiak, B. Levine, R. E. Schmidt, A. Garcia-Sastre, D. A. Leib, A. Pekosz, K. P. 
Knobeloch, I. Horak, and H. W. t. Virgin. 2007. IFN-stimulated gene 15 functions as a 
critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad 
Sci U S A 104:1371-1376. 
 
11. Giannakopoulos, N. V., E. Arutyunova, C. Lai, D. J. Lenschow, A. L. Haas, and H. W. 
Virgin. 2009. ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important 
for innate immune control of Sindbis virus. J Virol 83:1602-1610. 
 
12. Lai, C., J. J. Struckhoff, J. Schneider, L. Martinez-Sobrido, T. Wolff, A. Garcia-Sastre, 
D. E. Zhang, and D. J. Lenschow. 2009. Mice lacking the ISG15 E1 enzyme UbE1L 
demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted 
influenza B virus infection. J Virol 83:1147-1151. 
 
13. D'Cunha, J., E. Knight, Jr., A. L. Haas, R. L. Truitt, and E. C. Borden. 1996. 
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad 
Sci U S A 93:211-215. 
 
14. Padovan, E., L. Terracciano, U. Certa, B. Jacobs, A. Reschner, M. Bolli, G. C. Spagnoli, 
E. C. Borden, and M. Heberer. 2002. Interferon stimulated gene 15 constitutively 
produced by melanoma cells induces e-cadherin expression on human dendritic cells. 
Cancer Res 62:3453-3458. 
 
15. Owhashi, M., Y. Taoka, K. Ishii, S. Nakazawa, H. Uemura, and H. Kambara. 2003. 
Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor. 
Biochem Biophys Res Commun 309:533-539. 
 
16. Bogunovic, D., M. Byun, L. A. Durfee, A. Abhyankar, O. Sanal, D. Mansouri, S. Salem, 
I. Radovanovic, A. V. Grant, P. Adimi, N. Mansouri, S. Okada, V. L. Bryant, X. F. Kong, 
A. Kreins, M. M. Velez, B. Boisson, S. Khalilzadeh, U. Ozcelik, I. A. Darazam, J. W. 
Schoggins, C. M. Rice, S. Al-Muhsen, M. Behr, G. Vogt, A. Puel, J. Bustamante, P. 
Gros, J. M. Huibregtse, L. Abel, S. Boisson-Dupuis, and J. L. Casanova. 2012. 
Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited 
ISG15 deficiency. Science 337:1684-1688. 
 
17. Xia, Z. P., L. Sun, X. Chen, G. Pineda, X. Jiang, A. Adhikari, W. Zeng, and Z. J. Chen. 
2009. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 
461:114-119. 
 
18. Jiang, X., L. N. Kinch, C. A. Brautigam, X. Chen, F. Du, N. V. Grishin, and Z. J. Chen. 
2012. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates 
antiviral innate immune response. Immunity 36:959-973. 
 
175 
 
19. Zhao, C., C. Denison, J. M. Huibregtse, S. Gygi, and R. M. Krug. 2005. Human ISG15 
conjugation targets both IFN-induced and constitutively expressed proteins functioning in 
diverse cellular pathways. Proc Natl Acad Sci U S A 102:10200-10205. 
 
20. Giannakopoulos, N. V., J. K. Luo, V. Papov, W. Zou, D. J. Lenschow, B. S. Jacobs, E. C. 
Borden, J. Li, H. W. Virgin, and D. E. Zhang. 2005. Proteomic identification of proteins 
conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 336:496-
506. 
 
21. Hicke, L., H. L. Schubert, and C. P. Hill. 2005. Ubiquitin-binding domains. Nat Rev Mol 
Cell Biol 6:610-621. 
 
22. Hurley, J. H., S. Lee, and G. Prag. 2006. Ubiquitin-binding domains. Biochem J 399:361-
372. 
 
23. Matute, J. D., A. A. Arias, M. C. Dinauer, and P. J. Patino. 2005. p40phox: the last 
NADPH oxidase subunit. Blood Cells Mol Dis 35:291-302. 
 
24. Makeyev, A. V., and S. A. Liebhaber. 2002. The poly(C)-binding proteins: a multiplicity 
of functions and a search for mechanisms. RNA 8:265-278. 
 
25. You, F., H. Sun, X. Zhou, W. Sun, S. Liang, Z. Zhai, and Z. Jiang. 2009. PCBP2 
mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4. Nat 
Immunol 10:1300-1308. 
 
26. Zhou, X., F. You, H. Chen, and Z. Jiang. 2012. Poly(C)-binding protein 1 (PCBP1) 
mediates housekeeping degradation of mitochondrial antiviral signaling (MAVS). Cell 
Res 22:717-727. 
 
27. McGough, I. J., and P. J. Cullen. 2011. Recent advances in retromer biology. Traffic 
12:963-971. 
 
28. Cullen, P. J., and H. C. Korswagen. 2012. Sorting nexins provide diversity for retromer-
dependent trafficking events. Nat Cell Biol 14:29-37. 
 
29. Levine, B., J. E. Goldman, H. H. Jiang, D. E. Griffin, and J. M. Hardwick. 1996. Bc1-2 
protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci U S A 93:4810-
4815. 
 
30. Nava, V. E., A. Rosen, M. A. Veliuona, R. J. Clem, B. Levine, and J. M. Hardwick. 
1998. Sindbis virus induces apoptosis through a caspase-dependent, CrmA-sensitive 
pathway. J Virol 72:452-459. 
 
31. Orvedahl, A., S. MacPherson, R. Sumpter, Jr., Z. Talloczy, Z. Zou, and B. Levine. 2010. 
Autophagy protects against Sindbis virus infection of the central nervous system. Cell 
Host Microbe 7:115-127. 
176 
 
 
32. Joubert, P. E., S. W. Werneke, C. de la Calle, F. Guivel-Benhassine, A. Giodini, L. 
Peduto, B. Levine, O. Schwartz, D. J. Lenschow, and M. L. Albert. 2012. Chikungunya 
virus-induced autophagy delays caspase-dependent cell death. J Exp Med 209:1029-1047. 
 
33. Cadwell, K., J. Y. Liu, S. L. Brown, H. Miyoshi, J. Loh, J. K. Lennerz, C. Kishi, W. Kc, 
J. A. Carrero, S. Hunt, C. D. Stone, E. M. Brunt, R. J. Xavier, B. P. Sleckman, E. Li, N. 
Mizushima, T. S. Stappenbeck, and H. W. t. Virgin. 2008. A key role for autophagy and 
the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456:259-
263. 
 
34. Levine, B., and G. Kroemer. 2008. Autophagy in the pathogenesis of disease. Cell 
132:27-42. 
 
35. Deretic, V. 2012. Autophagy as an innate immunity paradigm: expanding the scope and 
repertoire of pattern recognition receptors. Curr Opin Immunol 24:21-31. 
 
36. Komatsu, M., H. Kurokawa, S. Waguri, K. Taguchi, A. Kobayashi, Y. Ichimura, Y. S. 
Sou, I. Ueno, A. Sakamoto, K. I. Tong, M. Kim, Y. Nishito, S. Iemura, T. Natsume, T. 
Ueno, E. Kominami, H. Motohashi, K. Tanaka, and M. Yamamoto. 2010. The selective 
autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through 
inactivation of Keap1. Nat Cell Biol 12:213-223. 
 
37. Fan, W., Z. Tang, D. Chen, D. Moughon, X. Ding, S. Chen, M. Zhu, and Q. Zhong. 2010. 
Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 
6:614-621. 
 
38. Jesenberger, V., and S. Jentsch. 2002. Deadly encounter: ubiquitin meets apoptosis. Nat 
Rev Mol Cell Biol 3:112-121. 
 
39. Klimstra, W. B., K. D. Ryman, K. A. Bernard, K. B. Nguyen, C. A. Biron, and R. E. 
Johnston. 1999. Infection of neonatal mice with sindbis virus results in a systemic 
inflammatory response syndrome. J Virol 73:10387-10398. 
 
40. Wang, E., E. Volkova, A. P. Adams, N. Forrester, S. Y. Xiao, I. Frolov, and S. C. 
Weaver. 2008. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 
26:5030-5039. 
 
41. Billiau, A. 2006. Anti-inflammatory properties of Type I interferons. Antiviral Res 
71:108-116. 
 
42. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Forster, M. Farlik, T. 
Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits 
interleukin-1 production and inflammasome activation. Immunity 34:213-223. 
 
177 
 
43. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, 
H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are 
effective therapeutic agents in lethal endotoxemia and function simultaneously as both 
TNF carriers and TNF antagonists. J Immunol 151:1548-1561. 
 
44. Merrill, J. C., J. You, C. Constable, S. E. Leeman, and S. Amar. 2011. Whole-body 
deletion of LPS-induced TNF-alpha factor (LITAF) markedly improves experimental 
endotoxic shock and inflammatory arthritis. Proc Natl Acad Sci U S A 108:21247-21252. 
 
45. Trgovcich, J., K. Ryman, P. Extrom, J. C. Eldridge, J. F. Aronson, and R. E. Johnston. 
1997. Sindbis virus infection of neonatal mice results in a severe stress response. 
Virology 227:234-238. 
 
46. Durfee, L. A., N. Lyon, K. Seo, and J. M. Huibregtse. 2010. The ISG15 conjugation 
system broadly targets newly synthesized proteins: implications for the antiviral function 
of ISG15. Mol Cell 38:722-732. 
 
 
 
 
